PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11573696-16 2001 In the post-MI + cyclosporin A group, the increase in protein phosphatase 1 activity was much less (18% vs 36%; P < 0.05), and the decrease in basal level of p16-phospholamban was markedly ameliorated (20% vs 79%; P < 0.01). Cyclosporine 17-30 cyclin-dependent kinase inhibitor 2A Rattus norvegicus 161-164 11573696-17 2001 The decreases in mRNA levels of Kv4.2 and Kv4.3 and I(to) density in the LV of the post-MI + cyclosporin A group were significantly less compared with the post-MI group. Cyclosporine 93-106 potassium voltage-gated channel subfamily D member 2 Rattus norvegicus 32-37 11573696-17 2001 The decreases in mRNA levels of Kv4.2 and Kv4.3 and I(to) density in the LV of the post-MI + cyclosporin A group were significantly less compared with the post-MI group. Cyclosporine 93-106 potassium voltage-gated channel subfamily D member 3 Rattus norvegicus 42-47 34990636-10 2022 Moreover, xenon treatment group showed augmented plasma levels of IL-6 cytokines (~5 fold) on day-35 post-ischemia, while no change was noticed in the IL-1beta, IL-4, IL-10, IL-13 and MCP-1 levels. Xenon 10-15 interleukin 4 Rattus norvegicus 161-165 34990636-10 2022 Moreover, xenon treatment group showed augmented plasma levels of IL-6 cytokines (~5 fold) on day-35 post-ischemia, while no change was noticed in the IL-1beta, IL-4, IL-10, IL-13 and MCP-1 levels. Xenon 10-15 interleukin 13 Rattus norvegicus 174-179 34990636-10 2022 Moreover, xenon treatment group showed augmented plasma levels of IL-6 cytokines (~5 fold) on day-35 post-ischemia, while no change was noticed in the IL-1beta, IL-4, IL-10, IL-13 and MCP-1 levels. Xenon 10-15 mast cell protease 1-like 1 Rattus norvegicus 184-189 35188731-7 2022 Analogously, the shaped materials presented xenon and krypton sorption isotherms correlated to their BET surface area and high predicted xenon/krypton selectivity, from 7.1 to 9.0. Xenon 44-49 delta/notch like EGF repeat containing Homo sapiens 101-104 35080182-1 2022 We report the synthesis of C3-symmetric cryptophanes decorated with three aromatic amine groups on the same CTB cap and their interaction with xenon. Xenon 143-148 chitobiase Homo sapiens 108-111 35317306-3 2022 Rodent studies have shown that xenon, a well-known anesthetic gas, can be neuroprotective when administered post-TBI. Xenon 31-36 gastrin Homo sapiens 62-65 2481186-2 1989 rCBF was studied by xenon-133 inhalation and single-photon emission computed tomography (SPECT) scan before and 1 h after oral administration of 25 mg captopril. Xenon 20-25 CCAAT/enhancer binding protein zeta Rattus norvegicus 0-4 35317306-4 2022 Gas inhalation therapy, however, the approach typically used for administering xenon, is expensive, inconvenient, and fraught with systemic side effects. Xenon 79-84 gastrin Homo sapiens 0-3 2693616-2 1989 rCBF was measured using xenon-133 inhalation and single photon emission computed tomography before and 20 minutes after the intravenous administration of 1 g acetazolamide. Xenon 24-29 CCAAT/enhancer binding protein zeta Rattus norvegicus 0-4 2770961-0 1989 [Xenon-enhanced CT CBF measurements in intracranial vascular malformations]. Xenon 1-6 CCAAT/enhancer binding protein zeta Rattus norvegicus 19-22 2770961-8 1989 From the xenon-enhanced CT scan and angiographic findings, the presence of steal phenomenon with venous congestion might be a cause of rCBF reduction in those cases where ischemia exists. Xenon 9-14 CCAAT/enhancer binding protein zeta Rattus norvegicus 135-139 3025234-1 1986 Regional CBF (rCBF) images obtained from xenon-enhanced computed tomography (XeCT) and single-photon emission computed tomography (SPECT) with N-isopropyl-p-[123I]iodoamphetamine (IMP) done with a rotating gamma-camera were compared in nine patients. Xenon 41-46 CCAAT/enhancer binding protein zeta Rattus norvegicus 9-12 3606327-1 1987 The relationship between age and regional cerebral blood flow (rCBF) activation for cognitive tasks was investigated with the xenon Xe 133 inhalation technique. Xenon 126-134 CCAAT/enhancer binding protein zeta Rattus norvegicus 63-67 2883602-0 1987 rCBF in brain tumours as measured by xenon enhanced CT. Xenon 37-42 CCAAT/enhancer binding protein zeta Rattus norvegicus 0-4 2883602-2 1987 On the other hand, our xenon-enhanced method has several advantages over the conventional isotope method and enables us to evaluate rCBF with a resolving power of 4 mm. Xenon 23-28 CCAAT/enhancer binding protein zeta Rattus norvegicus 132-136 3545653-7 1987 This finding with renin release stimulation at Xenon133 infusion in the renal artery is of great importance in judging results of investigations concerning renal blood flow and renin when the Xenon wash-out technique is used. Xenon 47-52 renin Homo sapiens 18-23 3545653-7 1987 This finding with renin release stimulation at Xenon133 infusion in the renal artery is of great importance in judging results of investigations concerning renal blood flow and renin when the Xenon wash-out technique is used. Xenon 47-52 renin Homo sapiens 177-182 3351919-1 1988 A 96 picosecond simulation of a myoglobin-xenon complex. Xenon 42-47 myoglobin Homo sapiens 32-41 3351919-2 1988 A 96 picosecond dynamics trajectory of myoglobin with five xenon-probe ligands in internal cavities is examined to study the effect of protein motions on ligand motion and internal cavity fluctuations. Xenon 59-64 myoglobin Homo sapiens 39-48 3244421-1 1988 A xenon-CT examination was performed on a patient who had received a STA-MCA bypass. Xenon 2-7 GCY Homo sapiens 69-72 3545653-3 1987 Immediately after the Xenon injection renal vein renin elevations on the investigated side were observed in 9/11 patients. Xenon 22-27 renin Homo sapiens 49-54 3491828-1 1986 Repeated bedside measurements of CBF have been made possible by the recent development of a mobile unit with 10 stationary detectors using the intravenous xenon-133 method. Xenon 155-160 CCAAT enhancer binding protein zeta Homo sapiens 33-36 3560222-0 1986 Computational studies of the interaction of myoglobin and xenon. Xenon 58-63 myoglobin Homo sapiens 44-53 3560222-1 1986 Computational studies are used to investigate the energies of xenon binding to myoglobin and to describe pathways through the protein interior for a metmyoglobin-xenon complex. Xenon 62-67 myoglobin Homo sapiens 79-88 3560222-1 1986 Computational studies are used to investigate the energies of xenon binding to myoglobin and to describe pathways through the protein interior for a metmyoglobin-xenon complex. Xenon 162-167 myoglobin Homo sapiens 79-88 3484790-4 1986 Specific clinical dilemmas that have been addressed with rCBF information from xenon-enhanced CT scanning include the following: In the patient with asymptomatic occlusive disease, is normal rCBF preserved? Xenon 79-84 CCAAT/enhancer binding protein zeta Rattus norvegicus 57-61 3099167-6 1986 This association of RNA polymerase II was apparent whether the cross-linking was performed by a 10-min UV irradiation of chilled cells with mercury vapor lamps or by a 40-microsecond irradiation of cells with a high-energy xenon flash lamp. Xenon 223-228 RNA polymerase II 215kD subunit Drosophila melanogaster 20-37 2949397-2 1986 rCBF was measured by intracarotid injection of 133 Xenon shortly before and at the time of the carotid artery occlusion, and again a few minutes after carotid flow was reestablished. Xenon 51-56 CCAAT/enhancer binding protein zeta Rattus norvegicus 0-4 3484790-11 1986 On the basis of experience with 155 patients, the management and understanding of cerebrovascular disease has been aided substantially by the incorporation of rCBF mapping by xenon-enhanced CT scan in the evaluation of these patients. Xenon 175-180 CCAAT/enhancer binding protein zeta Rattus norvegicus 159-163 6676970-0 1983 Xenon arc photocoagulation of proliferative diabetic retinopathy (a review of 2688 consecutive eyes in the format of the diabetic retinopathy study--DRS). Xenon 0-5 sushi repeat containing protein X-linked Homo sapiens 149-152 2984596-4 1985 The Xenon enhanced CT method has several advantages over the conventional isotope method and enables us to evaluate rCBF with the same resolving power as with the CT scan. Xenon 4-9 CCAAT/enhancer binding protein zeta Rattus norvegicus 116-120 6651982-1 1983 UNLABELLED: Using a new method for rCBF measurement by serial CT scanning with non-radioactive xenon enhancement, CBF was measured before and/or after microsurgical anastomosis in five cases of focal cerebral ischemia. Xenon 95-100 CCAAT/enhancer binding protein zeta Rattus norvegicus 35-39 6651982-1 1983 UNLABELLED: Using a new method for rCBF measurement by serial CT scanning with non-radioactive xenon enhancement, CBF was measured before and/or after microsurgical anastomosis in five cases of focal cerebral ischemia. Xenon 95-100 CCAAT enhancer binding protein zeta Homo sapiens 36-39 6601942-2 1983 Regional cerebral blood flow (rCBF) may be measured with a single-photon-emission computed tomograph (SPECT) after inhalation of xenon 133. Xenon 129-134 CCAAT/enhancer binding protein zeta Rattus norvegicus 30-34 6685038-2 1983 During passive compression of the muscle at rest 133-Xenon muscle clearance stopped when MTP reached diastolic arterial pressure (DAP) indicating that the muscle vascular bed was occluded. Xenon 53-58 metallothionein 1B Homo sapiens 89-92 3484686-0 1986 Mismatch between iodine-123 and xenon-133 SPECT rCBF measurement. Xenon 32-37 CCAAT/enhancer binding protein zeta Rattus norvegicus 48-52 3972917-1 1985 The effects of high inspired concentrations of xenon and krypton on regional CBF (rCBF) were assessed in the rat using [14C]iodoantipyrine and quantitative autoradiography. Xenon 47-52 CCAAT/enhancer binding protein zeta Rattus norvegicus 82-86 3972917-2 1985 Inhalation of 80% xenon for 1 or 2 min and inhalation of 40% xenon for 2 min were found to have significant effects on rCBF, including average increases of 75-96% in cerebral neocortical regions. Xenon 18-23 CCAAT/enhancer binding protein zeta Rattus norvegicus 119-123 3972917-2 1985 Inhalation of 80% xenon for 1 or 2 min and inhalation of 40% xenon for 2 min were found to have significant effects on rCBF, including average increases of 75-96% in cerebral neocortical regions. Xenon 61-66 CCAAT/enhancer binding protein zeta Rattus norvegicus 119-123 3972917-4 1985 If xenon inhalation produces effects on rCBF in humans similar to those observed in the rat, such effects could be an important source of error in xenon computed tomography rCBF studies. Xenon 3-8 CCAAT/enhancer binding protein zeta Rattus norvegicus 40-44 3972917-4 1985 If xenon inhalation produces effects on rCBF in humans similar to those observed in the rat, such effects could be an important source of error in xenon computed tomography rCBF studies. Xenon 147-152 CCAAT/enhancer binding protein zeta Rattus norvegicus 173-177 9895722-0 1985 Transient negative mobility of hot electrons in gaseous xenon. Xenon 56-61 alcohol dehydrogenase iron containing 1 Homo sapiens 31-34 6676970-3 1983 A critical analysis of the DRS gives clues for the greater amount of visual loss found with xenon than argon in the DRS. Xenon 92-97 sushi repeat containing protein X-linked Homo sapiens 27-30 6676970-3 1983 A critical analysis of the DRS gives clues for the greater amount of visual loss found with xenon than argon in the DRS. Xenon 92-97 sushi repeat containing protein X-linked Homo sapiens 116-119 7262408-3 1981 Xenon are photocoagulation, as carried out in the DRS, is attended by an increased risk of serious macular damage secondary to vitreoretinal traction. Xenon 0-5 sushi repeat containing protein X-linked Homo sapiens 50-53 7252476-1 1981 The bleaching of rhodopsin by short-duration flashes of a xenon discharge lamp was studied in vivo in the cat retina with the aid of a rapid, spectral-scan fundus reflectometer. Xenon 58-63 rhodopsin Homo sapiens 17-26 7306004-11 1981 Dithionite-reduced cytochrome b-245 formed a complex with CO, supplied as a saturated solution, which was dissociated with 26 microseconds illumination from a xenon flash lamp, and the recombination with CO had a half-time of approx. Xenon 159-164 mitochondrially encoded cytochrome b Homo sapiens 19-31 7163969-4 1982 Measurements of rCBF in the group of 50 patients using the intravenous xenon 133 technique showed that there was a significant decrease in the mean rCBF (47.5 +/- 1.4 ml/100 gm/min) as compared with 19 age-matched normal subjects (54.9 +/- 1.8 ml/100 gm/min. Xenon 71-76 CCAAT/enhancer binding protein zeta Rattus norvegicus 16-20 7163969-4 1982 Measurements of rCBF in the group of 50 patients using the intravenous xenon 133 technique showed that there was a significant decrease in the mean rCBF (47.5 +/- 1.4 ml/100 gm/min) as compared with 19 age-matched normal subjects (54.9 +/- 1.8 ml/100 gm/min. Xenon 71-76 CCAAT/enhancer binding protein zeta Rattus norvegicus 148-152 7048641-1 1982 The objective of this investigation was to correlate Xenon-133 inhalation rCBF measurements with the pattern of cortical arterial filling on intravenous DSA in 18 patients with unilateral internal carotid artery occlusion. Xenon 53-58 CCAAT/enhancer binding protein zeta Rattus norvegicus 74-78 6812546-6 1982 Investigations of regional cerebral blood flow by the radioactive Xenon technique reveal that there is neuronal activity in the SMA of both sides during a continual series of voluntary movements, and that this even occurs when the movement is thought of, but not executed. Xenon 66-71 survival of motor neuron 1, telomeric Homo sapiens 128-131 7291308-1 1981 Radioisotopes of xenon or krypton are generally used as the inert diffusible indicators in regional cerebral blood flow (rCBF) studies. Xenon 17-22 CCAAT/enhancer binding protein zeta Rattus norvegicus 121-125 6968606-2 1980 A survey of the Xenon-133 techniques for measurement of regional cerebral blood flow, rCBF, in man is presented. Xenon 16-21 CCAAT/enhancer binding protein zeta Rattus norvegicus 86-90 484913-2 1979 Reduction in plasma fibrinogen was associated with a sustained reduction in plasma and blood viscosity, and a sustained increase in nutritional skin blood flow, measured by a Xenon-133 clearance technique (P less than 0.001). Xenon 175-180 fibrinogen beta chain Homo sapiens 20-30 518909-2 1979 1H-NMR spectra have been recorded for sperm whale met-aquo myoglobin intercalated with xenon, cyclopropane, mercuric triiodide and auric triiodide. Xenon 87-92 myoglobin Physeter catodon 59-68 522961-1 1979 Regional cerebral blood flow (rCBF) was determined in man by Xenon-133 intravenous bolus injection technique. Xenon 61-66 CCAAT/enhancer binding protein zeta Rattus norvegicus 30-34 435132-1 1979 Regional cerebral blood flow (rCBF) was measured by xenon 133 inhalation in 36 patients with vertebrobasilar arterial insufficiency (VBI), three patients with brain stem infarction, and 15 age-matched normal controls before and after inducing postural hypotension. Xenon 52-57 CCAAT/enhancer binding protein zeta Rattus norvegicus 30-34 899720-2 1977 RCBF was measured in 14 cases using the intra-arterial-133-Xenon clearance technique. Xenon 59-64 CCAAT/enhancer binding protein zeta Rattus norvegicus 0-4 450176-1 1979 In 22 patients the regional cerebral blood flow (rCBF) was measured after intra-arterial injection of xenon 133Xe. Xenon 102-107 CCAAT/enhancer binding protein zeta Rattus norvegicus 49-53 431507-1 1979 Clearance of Xenon 133 following intravenous injection has been used to perform atraumatic measurements of regional cerebral blood flow (rCBF). Xenon 13-18 CCAAT/enhancer binding protein zeta Rattus norvegicus 137-141 431507-2 1979 rCBF was computed by a two-compartmental analysis of the clearance curves associated with a correction for Xenon recirculation based on the end-tidal tracer concentration. Xenon 107-112 CCAAT/enhancer binding protein zeta Rattus norvegicus 0-4 431507-8 1979 Such precision makes the atraumatic measurements of rCBF by intravenous injection of Xenon valuable for clinical applications. Xenon 85-90 CCAAT/enhancer binding protein zeta Rattus norvegicus 52-56 5406897-0 1969 Effects of treatment with radon waters in Swieradow spa on tissue blood flow determined by means of radioactive xenon. Xenon 112-117 surfactant protein A2 Homo sapiens 52-55 879336-4 1977 During vasopressin infusion, the heterogeneity of oxygen saturation and xenon activity in the portal branches increased significantly. Xenon 72-77 arginine vasopressin Homo sapiens 7-18 1151790-2 1975 Human rhodopsin in vivo was flash bleached by a 600 musec xenon flash which could deliver to the retina up to 15 rod-equivalent quanta per rhodopsin molecule, and the fraction bleached measured by fundus reflexion densitometry. Xenon 58-63 rhodopsin Homo sapiens 139-148 1151790-2 1975 Human rhodopsin in vivo was flash bleached by a 600 musec xenon flash which could deliver to the retina up to 15 rod-equivalent quanta per rhodopsin molecule, and the fraction bleached measured by fundus reflexion densitometry. Xenon 58-63 rhodopsin Homo sapiens 6-15 5445459-0 1970 The thermodynamics of absorption of xenon by myoglobin. Xenon 36-41 myoglobin Homo sapiens 45-54 33283943-1 2021 PURPOSE: To demonstrate the feasibility of generating red blood cell (RBC) and tissue/plasma (TP)-specific gas-phase (GP) depolarization maps using xenon-polarization transfer contrast (XTC) MR imaging. Xenon 148-153 ring finger protein 130 Homo sapiens 118-120 5893727-0 1965 Binding of xenon to sperm whale myoglobin. Xenon 11-16 myoglobin Physeter catodon 32-41 32897053-4 2020 We demonstrate that RBP, with a tunable ribose-binding site and further engineered to bind xenon, enables the quantitation of ribose over a wide concentration range (nM to mM). Xenon 91-96 retinol binding protein 4 Homo sapiens 20-23 33885059-2 2021 At the MP2 level of theory, the predicted Xe-Os bond length (2.407 A) is between the standard double (2.51 A) and triple (2.31 A) bond lengths. Xenon 42-44 tryptase pseudogene 1 Homo sapiens 7-10 33028822-1 2020 The photoionization of xenon atoms in the 70-100 eV range reveals several fascinating physical phenomena such as a giant resonance induced by the dynamic rearrangement of the electron cloud after photon absorption, an anomalous branching ratio between intermediate Xe+ states separated by the spin-orbit interaction and multiple Auger decay processes. Xenon 23-28 spindlin 1 Homo sapiens 293-297 33246487-7 2020 Xenon treatment resulted in significant increases in Iba1-positive microglia and GFAP-positive reactive astrocytes that was associated with neuronal preservation. Xenon 0-5 allograft inflammatory factor 1 Rattus norvegicus 53-57 33246487-7 2020 Xenon treatment resulted in significant increases in Iba1-positive microglia and GFAP-positive reactive astrocytes that was associated with neuronal preservation. Xenon 0-5 glial fibrillary acidic protein Rattus norvegicus 81-85 31663253-4 2020 SC-SC sorption of N 2 , CO 2 , Xe, and AcMe by p- G 2 BDS is explored under various conditions and X-ray diffraction provides a measurement of the high pressure Xe and CO 2 sorption isotherms. Xenon 31-33 delta like non-canonical Notch ligand 1 Homo sapiens 47-53 32814938-2 2020 A protein complementation assay (PCA), split TEM-1 beta-lactamase, interacts with xenon at the interface of the TEM-1 fragments. Xenon 82-87 CD248 molecule Homo sapiens 45-50 32467161-6 2020 General anesthetics, such as chloroform, isoflurane, diethyl ether, xenon, and propofol, disrupt lipid rafts and activate PLD2. Xenon 68-73 phospholipase D2 Homo sapiens 122-126 32622527-0 2020 Xenon blunts NF-kappaB/NLRP3 inflammasome activation and improves acute onset of accelerated and severe lupus nephritis in mice. Xenon 0-5 NLR family, pyrin domain containing 3 Mus musculus 23-28 32622527-5 2020 The effects of xenon were mediated primarily by deceasing serum levels of anti-double stranded DNA autoantibody, inhibiting reactive oxygen species production, NF-kappaB/NLRP3 inflammasome activation, ICAM-1 expression, glomerular deposition of IgG and C3 and apoptosis, in the kidney; and enhancing renal hypoxia inducible factor 1-alpha expression. Xenon 15-20 NLR family, pyrin domain containing 3 Mus musculus 170-175 32622527-5 2020 The effects of xenon were mediated primarily by deceasing serum levels of anti-double stranded DNA autoantibody, inhibiting reactive oxygen species production, NF-kappaB/NLRP3 inflammasome activation, ICAM-1 expression, glomerular deposition of IgG and C3 and apoptosis, in the kidney; and enhancing renal hypoxia inducible factor 1-alpha expression. Xenon 15-20 intercellular adhesion molecule 1 Mus musculus 201-207 32622527-5 2020 The effects of xenon were mediated primarily by deceasing serum levels of anti-double stranded DNA autoantibody, inhibiting reactive oxygen species production, NF-kappaB/NLRP3 inflammasome activation, ICAM-1 expression, glomerular deposition of IgG and C3 and apoptosis, in the kidney; and enhancing renal hypoxia inducible factor 1-alpha expression. Xenon 15-20 hypoxia inducible factor 1, alpha subunit Mus musculus 306-338 32622527-6 2020 Proteomic analysis revealed that the treatment with xenon downregulated renal NLRP3 inflammasome-mediated cellular signaling. Xenon 52-57 NLR family, pyrin domain containing 3 Mus musculus 78-83 32731517-8 2020 Moreover, exploring the Cambridge Structural Database (CSD) and Inorganic Crystal Structure Database (ICSD), it is demonstrated that NgB interactions are crucial in governing the X-ray packing of xenon derivatives. Xenon 196-201 neuroglobin Homo sapiens 133-136 32227848-1 2020 Threshold collision-induced dissociation (TCID) of Th(OH)3+(H2O)n (n = 1 - 4) with xenon was performed using a guided ion beam tandem mass spectrometer (GIBMS). Xenon 83-88 SS nuclear autoantigen 1 Homo sapiens 67-76 31663253-6 2020 np- G 2 BDS reverts to x CO 2 @ p- G 2 BDS or x Xe@ p- G 2 BDS ( x = variable) simply by applying pressure of CO 2 or Xe, respectively. Xenon 48-50 delta like non-canonical Notch ligand 1 Homo sapiens 1-7 31663253-6 2020 np- G 2 BDS reverts to x CO 2 @ p- G 2 BDS or x Xe@ p- G 2 BDS ( x = variable) simply by applying pressure of CO 2 or Xe, respectively. Xenon 118-120 delta like non-canonical Notch ligand 1 Homo sapiens 1-7 31598974-0 2019 Xenon modulates synaptic transmission to rat hippocampal CA3 neurons at both pre- and postsynaptic sites. Xenon 0-5 carbonic anhydrase 3 Rattus norvegicus 57-60 32508522-0 2020 The first dual-phase xenon TPC equipped with silicon photomultipliers and characterisation with 37 Ar. Xenon 21-26 solute carrier family 25 member 19 Homo sapiens 27-30 32444566-9 2020 Immuno fluorescence localization of ZO-1 (XY) showed reduced density of ZO-1 rings and incomplete ring-like staining in the 45% FiO2- 50% xenon group at 32 C compared with other groups. Xenon 138-143 tight junction protein 1 Homo sapiens 36-40 32444566-11 2020 Secretion of IL-6 in 21% FiO2 with xenon group at 32 C was less than that of the control group. Xenon 35-40 interleukin 6 Homo sapiens 13-17 32444566-12 2020 The secretion of IL-8 in 45% FiO2 with xenon at 32 C was greater than that of other groups. Xenon 39-44 C-X-C motif chemokine ligand 8 Homo sapiens 17-21 32944489-1 2020 Using a multi-turn time-of-flight (TOF) mass spectrometer, we have extracted a single xenon isotope ion, 129Xe+, from its orbit at given a lap number without disturbing the rest of isotopes. Xenon 86-91 LAP Homo sapiens 139-142 31414957-0 2019 Effect of Acute and Chronic Xenon Inhalation on Erythropoietin, Hematological Parameters, and Athletic Performance. Xenon 28-33 erythropoietin Homo sapiens 48-62 31414957-3 2019 EPO was measured at baseline, during and post xenon inhalation. Xenon 46-51 erythropoietin Homo sapiens 0-3 31414957-9 2019 CONCLUSIONS: Acute exposure to sub-anesthetic doses of xenon caused a consistent increase in EPO, and 7 consecutive days of xenon inhalation significantly expanded plasma volume. Xenon 55-60 erythropoietin Homo sapiens 93-96 31720611-2 2019 This dianion is shown to form stable [NgBeB11(CN)11]2- (Ng = He, Ne, Ar, Kr and Xe) compounds associated with either a Ng-Be or Ng-B bond. Xenon 80-82 neuroglobin Homo sapiens 119-123 31483426-3 2019 According to the natural population analysis, the Xe atom donated 0.12-0.77 electrons to HM(BO2)2 and 0.14-0.41 electrons to LiM(BO2)2 when they combined, leading to metastable charge-transfer compounds in most cases. Xenon 50-52 PDZ and LIM domain 5 Homo sapiens 125-128 31619741-3 2019 In this study, by using magnetic resonance thermometry with hyperpolarized xenon, we produce the first direct evidence of UCP1-independent BAT thermogenesis in knockout mice. Xenon 75-80 uncoupling protein 1 (mitochondrial, proton carrier) Mus musculus 122-126 31483426-4 2019 The nature of bonding between xenon and HM(BO2)2/LiM(BO2)2 was found to be related to its location. Xenon 30-35 PDZ and LIM domain 5 Homo sapiens 49-52 31105058-1 2019 Irradiation of platelets with filtered xenon (fXe) flash for pathogen inactivation increases PAC-1 binding, but does not cause discernible aggregation. Xenon 39-44 dual specificity phosphatase 2 Homo sapiens 93-98 31576217-3 2019 Moreover, X-ray diffraction at 100 K under a high pressure of dioxygen, a physiological ligand of Ngb, unravelled the existence of a storage site for O2 in Ngb which coincides with Xe-III, a previously described docking site for xenon or krypton. Xenon 181-187 neuroglobin Mus musculus 98-101 31576217-3 2019 Moreover, X-ray diffraction at 100 K under a high pressure of dioxygen, a physiological ligand of Ngb, unravelled the existence of a storage site for O2 in Ngb which coincides with Xe-III, a previously described docking site for xenon or krypton. Xenon 181-187 neuroglobin Mus musculus 156-159 31576217-3 2019 Moreover, X-ray diffraction at 100 K under a high pressure of dioxygen, a physiological ligand of Ngb, unravelled the existence of a storage site for O2 in Ngb which coincides with Xe-III, a previously described docking site for xenon or krypton. Xenon 229-234 neuroglobin Mus musculus 98-101 31576217-3 2019 Moreover, X-ray diffraction at 100 K under a high pressure of dioxygen, a physiological ligand of Ngb, unravelled the existence of a storage site for O2 in Ngb which coincides with Xe-III, a previously described docking site for xenon or krypton. Xenon 229-234 neuroglobin Mus musculus 156-159 31122738-6 2019 Xenon treatment reduced white matter loss in the contralateral corpus callosum and neuronal loss in the contralateral hippocampal CA1 and dentate gyrus areas at 20 months. Xenon 0-5 carbonic anhydrase 1 Mus musculus 130-133 30650230-5 2019 The part of the biosensor that enables detection by means of 129 Xe NMR spectroscopy, which is linked to the CrAsH moiety by a spacer, is based on a cryptophane core that is fully suited to reversibly host xenon. Xenon 206-211 asparaginase and isoaspartyl peptidase 1 Homo sapiens 109-114 31674547-3 2019 HHG spectra were recorded for different backing pressures and gases (Ar, Xe) as a function of driver pulse ellipticity. Xenon 73-75 luteinizing hormone/choriogonadotropin receptor Homo sapiens 0-3 30174885-0 2018 Pulmonary static inflation with 50% xenon attenuates decline in tissue factor in patients undergoing Stanford type A acute aortic dissection repair. Xenon 36-41 coagulation factor III, tissue factor Homo sapiens 64-77 31555023-3 2019 The authors give values of the coefficients c 1, c 2, c 3 for six gases: Ne, Ar, Xe, N2, CO2, and N2O. Xenon 81-83 heterogeneous nuclear ribonucleoprotein C Homo sapiens 44-57 29189947-2 2018 METHODS: Xenon flash ERG was done in 18 eyes of nine RP patients and 20 normal eyes. Xenon 9-14 ETS transcription factor ERG Homo sapiens 21-24 30106783-0 2018 Xenon Myocardial Protection in Cardiac Surgery: Effective around the Clock? Xenon 0-5 clock circadian regulator Homo sapiens 69-74 29679839-3 2018 Recently, it was discovered that xenon can boost erythropoietin production, and it has been used as a performance-enhancing agent in international sports competitions such as the Sochi Olympic Games. Xenon 33-38 erythropoietin Homo sapiens 49-63 30174885-11 2018 Pulmonary static inflation with 50% xenon attenuates decline in TF in patients undergoing Stanford type A AAD repair. Xenon 36-41 coagulation factor III, tissue factor Homo sapiens 64-66 27906765-1 2018 Bedside xenon-enhanced computerized tomography (XeCT) enables measurements of regional cerebral blood flow (rCBF) during neurosurgical intensive care. Xenon 8-13 CCAAT/enhancer binding protein zeta Rattus norvegicus 108-112 29864148-0 2018 Xenon-inhibition of the MscL mechano-sensitive channel and the CopB copper ATPase under different conditions suggests direct effects on these proteins. Xenon 0-5 COPI coat complex subunit beta 1 Homo sapiens 63-67 29864148-0 2018 Xenon-inhibition of the MscL mechano-sensitive channel and the CopB copper ATPase under different conditions suggests direct effects on these proteins. Xenon 0-5 dynein axonemal heavy chain 8 Homo sapiens 75-81 29864148-6 2018 Similarly, the activity of the Enterococcus hirae CopB copper ATPase, reconstituted into proteoliposomes, was inhibited by xenon. Xenon 123-128 COPI coat complex subunit beta 1 Homo sapiens 50-54 29864148-6 2018 Similarly, the activity of the Enterococcus hirae CopB copper ATPase, reconstituted into proteoliposomes, was inhibited by xenon. Xenon 123-128 dynein axonemal heavy chain 8 Homo sapiens 62-68 29864148-7 2018 However, the CopB ATPase activity was also inhibited by xenon when CopB was in a solubilized state. Xenon 56-61 COPI coat complex subunit beta 1 Homo sapiens 13-17 29864148-7 2018 However, the CopB ATPase activity was also inhibited by xenon when CopB was in a solubilized state. Xenon 56-61 dynein axonemal heavy chain 8 Homo sapiens 18-24 29864148-7 2018 However, the CopB ATPase activity was also inhibited by xenon when CopB was in a solubilized state. Xenon 56-61 COPI coat complex subunit beta 1 Homo sapiens 67-71 29627444-6 2018 Sevoflurane, desflurane, and isoflurane as well as xenon and argon accelerated by a factor of ~1.5 channel desensitization of the main ASICs of the central nervous system: homomeric ASIC1a and heteromeric ASIC1a/2a and ASIC1a/2b. Xenon 51-56 acid-sensing (proton-gated) ion channel 1 Mus musculus 182-188 29627444-6 2018 Sevoflurane, desflurane, and isoflurane as well as xenon and argon accelerated by a factor of ~1.5 channel desensitization of the main ASICs of the central nervous system: homomeric ASIC1a and heteromeric ASIC1a/2a and ASIC1a/2b. Xenon 51-56 acid-sensing (proton-gated) ion channel 1 Mus musculus 205-211 29627444-6 2018 Sevoflurane, desflurane, and isoflurane as well as xenon and argon accelerated by a factor of ~1.5 channel desensitization of the main ASICs of the central nervous system: homomeric ASIC1a and heteromeric ASIC1a/2a and ASIC1a/2b. Xenon 51-56 acid-sensing (proton-gated) ion channel 1 Mus musculus 205-211 29575062-0 2018 Restored response to ADP downstream of purinergic P2Y12 receptor in apheresis platelets after pathogen-reducing xenon flash treatment. Xenon 112-117 purinergic receptor P2Y12 Homo sapiens 50-55 29575062-1 2018 BACKGROUND: Our previous study revealed that pathogen-reducing filtered xenon flash-treated platelets (fXe-PLTs) showed sustained aggregation in response to adenosine diphosphate (ADP), but apheresis-collected PLTs (Aph-PLTs) showed reversible aggregation. Xenon 72-77 acylaminoacyl-peptide hydrolase Homo sapiens 216-219 29285980-6 2018 Xenon (50% atm) applied 1 h after blast exposure reduced injury 24 h (p < 0.01), 48 h (p < 0.05), and 72 h (p < 0.001) later, compared with untreated control injury. Xenon 0-5 ATM serine/threonine kinase Homo sapiens 11-14 29407909-8 2018 The program caver3.0 was used to identify tunnels inside DHP obtained from MD simulation snapshots that are consistent with the importance of the Xe binding site, which is located at the central intersection of the tunnels. Xenon 146-148 dihydropyrimidinase Homo sapiens 57-60 29448700-0 2018 UV Photoluminescence of Alumino-Germano-Silicate Glass Optical Fiber Incorporated with Gd2O3 Nano-Particles Upon Illumination of Xenon-Lamp. Xenon 129-134 lysosomal associated membrane protein 3 Homo sapiens 135-139 29448700-5 2018 To investigate the photoluminescence (PL) property for UV sensor applications, the PL of the fiber was obtained by illumination of the Xenon-lamp. Xenon 135-140 lysosomal associated membrane protein 3 Homo sapiens 141-145 29623938-11 2018 At 72 hours after reperfusion, delayed xenon post-conditioning remarkably enhanced hindlimb motor function, increased the number of normal neurons at the injury site, decreased Iba1 levels, and inhibited interleukin-6 and interleukin-10 levels in the spinal cord. Xenon 39-44 interleukin-6 Oryctolagus cuniculus 204-217 29623938-11 2018 At 72 hours after reperfusion, delayed xenon post-conditioning remarkably enhanced hindlimb motor function, increased the number of normal neurons at the injury site, decreased Iba1 levels, and inhibited interleukin-6 and interleukin-10 levels in the spinal cord. Xenon 39-44 interleukin-10 Oryctolagus cuniculus 222-236 29623938-13 2018 These findings indicate that delayed xenon post-conditioning after spinal cord injury improves the recovery of neurological function by reducing microglial activation and the release of interleukin-6 and interleukin-10. Xenon 37-42 interleukin-6 Oryctolagus cuniculus 186-199 29623938-13 2018 These findings indicate that delayed xenon post-conditioning after spinal cord injury improves the recovery of neurological function by reducing microglial activation and the release of interleukin-6 and interleukin-10. Xenon 37-42 interleukin-10 Oryctolagus cuniculus 204-218 29147921-0 2018 Correction to: Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial. Xenon 30-35 erythropoietin Homo sapiens 46-60 29518790-0 2018 Impact of Xenon on CLIC4 and Bcl-2 Expression in Lipopolysaccharide and Hypoxia-Ischemia-Induced Periventricular White Matter Damage. Xenon 10-15 chloride intracellular channel 4 Homo sapiens 19-24 29272942-5 2017 In this paper, molecular dynamics was applied to simulate the network variations in a type of NBS glass and the changes in hardness after xenon irradiation. Xenon 138-143 nibrin Homo sapiens 94-97 29021779-15 2017 CONCLUSION: In animals treated with 50 vol% xenon (for 1 h) after SAH, a less pronounced neuronal damage was observed for the ipsilateral hippocampal regions CA3 and DG, when compared to the control group. Xenon 44-49 carbonic anhydrase 3 Rattus norvegicus 158-161 29150078-2 2017 In this study, a bimodal fluorescence/129Xe NMR probe containing a xenon host, a fluorescent moiety and a therapeutic antibody has been designed to target the Epidermal Growth Factor Receptors (EGFR) overexpressed in cancer cells. Xenon 67-72 epidermal growth factor receptor Homo sapiens 159-192 29150078-2 2017 In this study, a bimodal fluorescence/129Xe NMR probe containing a xenon host, a fluorescent moiety and a therapeutic antibody has been designed to target the Epidermal Growth Factor Receptors (EGFR) overexpressed in cancer cells. Xenon 67-72 epidermal growth factor receptor Homo sapiens 194-198 29221388-3 2017 Reactions of SmS+ with Xe, CO, and O2 are examined. Xenon 23-25 spermine synthase Homo sapiens 13-16 29108649-7 2017 A new gas binding site on the proximal side of the heme has also been characterized, using xenon pressure on a Ngb mutant (V140W) that binds CO with a similar rate and affinity to the wild-type, despite a reshaping of the internal cavity. Xenon 91-96 neuroglobin Mus musculus 111-114 27341380-2 2017 Besides its anaesthetic properties, Xenon promotes the endogenous erythropoietin biosynthesis and thus has been enlisted as prohibited substance by the World Anti-Doping Agency (WADA). Xenon 36-41 erythropoietin Homo sapiens 66-80 28863710-5 2017 Calculations of accelerating cell geometries and ion trajectories determined the dependence of beam expansion half-angle on normalized perveance based on the measurements of the spatial distributions of the xenon plasma parameters at the IEG entrance for a xenon flow rate q 0.2 mg/s and an incident RF power Pin <= 250 W at a driving frequency f = 2 MHz. Xenon 257-262 dynein light chain LC8-type 1 Homo sapiens 311-314 28636798-8 2017 Fluorescence-based flow cytometry and xenon MRI demonstrated binding of the biosensor specifically to Cldn4-expressing cells. Xenon 38-43 claudin 4 Homo sapiens 102-107 28409925-4 2017 Thermally, two conformers of 5MOI could be trapped in xenon matrixes at 16 K. Upon annealing the xenon matrix to temperatures about 30-40 K, the higher-energy syn form converted to the ground-state anti conformer. Xenon 97-102 synemin Homo sapiens 159-162 28398653-9 2017 The effects of xenon were mimicked and improved by the N-methyl-d-aspartate glutamate receptor antagonist memantine and xenon itself appeared to work by antagonizing N-methyl-d-aspartate receptors. Xenon 15-20 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 55-94 26939898-0 2016 Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial. Xenon 15-20 erythropoietin Homo sapiens 31-45 28221806-1 2017 We simultaneously measured the absorption and emission of single conjugated polymer poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MEH-PPV) molecules in a poly(methyl methacrylate) (PMMA) matrix using near-critical xenon to enhance the photothermal contrast for direct absorption measurements. Xenon 227-232 epoxide hydrolase 1 Homo sapiens 143-146 28272227-9 2017 After surgery, the levels of interleukin-6 (IL-6), tumor necrosis factor alpha, and thromboxane B2 decreased by 23.5%, 9.1%, and 30.2%, respectively, in the xenon group, but increased by 10.8%, 26.2%, and 26.4%, respectively, in the control group. Xenon 157-162 interleukin 6 Homo sapiens 29-42 28272227-9 2017 After surgery, the levels of interleukin-6 (IL-6), tumor necrosis factor alpha, and thromboxane B2 decreased by 23.5%, 9.1%, and 30.2%, respectively, in the xenon group, but increased by 10.8%, 26.2%, and 26.4%, respectively, in the control group. Xenon 157-162 interleukin 6 Homo sapiens 44-48 28272227-9 2017 After surgery, the levels of interleukin-6 (IL-6), tumor necrosis factor alpha, and thromboxane B2 decreased by 23.5%, 9.1%, and 30.2%, respectively, in the xenon group, but increased by 10.8%, 26.2%, and 26.4%, respectively, in the control group. Xenon 157-162 tumor necrosis factor Homo sapiens 51-78 28272227-10 2017 Moreover, IL-10 levels increased by 28% in the xenon group and decreased by 7.5% in the control group. Xenon 47-52 interleukin 10 Homo sapiens 10-15 28272227-11 2017 There were significant time and treatment-time interaction effects on methane dicarboxylic aldehyde (P = 0.000 and P = 0.050, respectively) and myeloperoxidase (P = 0.000 and P = 0.001 in xenon and control groups, respectively). Xenon 188-193 myeloperoxidase Homo sapiens 144-159 27933561-0 2017 Comment on "Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial". Xenon 27-32 erythropoietin Homo sapiens 43-57 27933562-1 2017 : Comment on "Sub-Anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial". Xenon 29-34 erythropoietin Homo sapiens 45-59 26939898-2 2016 Xenon is supposed to trigger the production of hypoxia-inducible factor 1alpha (HIF-1alpha) and subsequently erythropoietin, but data are limited to in vivo experimental work. Xenon 0-5 hypoxia inducible factor 1 subunit alpha Homo sapiens 47-78 26939898-2 2016 Xenon is supposed to trigger the production of hypoxia-inducible factor 1alpha (HIF-1alpha) and subsequently erythropoietin, but data are limited to in vivo experimental work. Xenon 0-5 hypoxia inducible factor 1 subunit alpha Homo sapiens 80-90 26939898-2 2016 Xenon is supposed to trigger the production of hypoxia-inducible factor 1alpha (HIF-1alpha) and subsequently erythropoietin, but data are limited to in vivo experimental work. Xenon 0-5 erythropoietin Homo sapiens 109-123 26939898-3 2016 Therefore we evaluated the effect of xenon on erythropoietin levels in healthy persons. Xenon 37-42 erythropoietin Homo sapiens 46-60 26939898-8 2016 RESULTS: The administration of xenon significantly increased erythropoietin levels 8 h after exposure (1.34 [+-0.368]; p = 0.008), peaking at 24 h compared to the baseline values (1.45 [+-0.498]; p = 0.01) and remained traceable in blood and exhalation probes until 24 h after exposure. Xenon 31-36 erythropoietin Homo sapiens 61-75 26939898-12 2016 CONCLUSION: The present study presents first evidence about a xenon-induced effect on increased erythropoietin levels in healthy volunteers. Xenon 62-67 erythropoietin Homo sapiens 96-110 27657869-6 2016 Moreover, we demonstrate that a chemically inert tip whose apex is terminated by a xenon atom cannot induce the reaction because of a weak interaction with porphycene and a strong relaxation of xenon on the tip as contact to the molecule is formed. Xenon 83-88 TOR signaling pathway regulator Homo sapiens 49-52 27518588-1 2016 A novel form of ion-tracks, namely nanogrooves and hillocks, are observed on CaF2 after irradiation with xenon and lead ions of about 100 MeV kinetic energy. Xenon 105-110 CCR4-NOT transcription complex subunit 8 Homo sapiens 77-81 27657869-6 2016 Moreover, we demonstrate that a chemically inert tip whose apex is terminated by a xenon atom cannot induce the reaction because of a weak interaction with porphycene and a strong relaxation of xenon on the tip as contact to the molecule is formed. Xenon 194-199 TOR signaling pathway regulator Homo sapiens 49-52 27657869-6 2016 Moreover, we demonstrate that a chemically inert tip whose apex is terminated by a xenon atom cannot induce the reaction because of a weak interaction with porphycene and a strong relaxation of xenon on the tip as contact to the molecule is formed. Xenon 194-199 TOR signaling pathway regulator Homo sapiens 207-210 30074728-1 2016 Xenon flash lamp is used by most analytical instruments and medical equipments as light sources whose spectral characteristics exert a tremendous influence on the property of instruments and medical equipments. Xenon 0-5 lysosomal associated membrane protein 3 Homo sapiens 12-16 27689284-2 2016 In the present study, we report on the ability of slow highly charged xenon ions (^{129}Xe^{Q+}) to form three different types of nanostructures on the LiF(100) surface. Xenon 70-75 LIF interleukin 6 family cytokine Homo sapiens 152-155 27538649-0 2016 Xenon-delayed postconditioning attenuates spinal cord ischemia/reperfusion injury through activation AKT and ERK signaling pathways in rats. Xenon 0-5 AKT serine/threonine kinase 1 Rattus norvegicus 101-104 27538649-0 2016 Xenon-delayed postconditioning attenuates spinal cord ischemia/reperfusion injury through activation AKT and ERK signaling pathways in rats. Xenon 0-5 Eph receptor B1 Rattus norvegicus 109-112 27538649-11 2016 These results suggest that xenon-delayed postconditioning improves neurological outcomes to spinal cord I/R injury in rats through the activation of the AKT and ERK signaling pathways. Xenon 27-32 AKT serine/threonine kinase 1 Rattus norvegicus 153-156 27538649-11 2016 These results suggest that xenon-delayed postconditioning improves neurological outcomes to spinal cord I/R injury in rats through the activation of the AKT and ERK signaling pathways. Xenon 27-32 Eph receptor B1 Rattus norvegicus 161-164 27377260-3 2016 Herein, we report the selective Xe uptake in a crystalline porous organic oligomeric molecule, noria, and its structural analogue, PgC-noria, under ambient conditions. Xenon 32-34 progastricsin Homo sapiens 131-134 30074728-2 2016 In order to study the effects of pulsed Xenon discharge circuit parameters and geometric parameters on the spectral characteristics, theoretical analysis has been conducted to Xenon lamp emitting process with the gas discharge theory. Xenon 40-45 lysosomal associated membrane protein 3 Homo sapiens 182-186 30074728-2 2016 In order to study the effects of pulsed Xenon discharge circuit parameters and geometric parameters on the spectral characteristics, theoretical analysis has been conducted to Xenon lamp emitting process with the gas discharge theory. Xenon 176-181 lysosomal associated membrane protein 3 Homo sapiens 182-186 30074728-3 2016 The spectroscopic detection system has been designed to conduct experimental detection to the spectral characteristics of pulsed Xenon lamp with different parameters. Xenon 129-134 lysosomal associated membrane protein 3 Homo sapiens 135-139 30074728-4 2016 The experimental results show that the emission spectra of Xenon flash lamp contain both line and continuous radiation. Xenon 59-64 lysosomal associated membrane protein 3 Homo sapiens 71-75 27341298-2 2016 The noble gas xenon accommodates into four transiently enlarged hydrophobic cavities located in the well-folded core of human PrP(23-230) as detected by [(1)H, (15)N]-HSQC spectroscopy. Xenon 14-19 prion protein Homo sapiens 126-129 27341298-4 2016 Xenon bound PrP was modelled by restraint molecular dynamics. Xenon 0-5 prion protein Homo sapiens 12-15 26095795-2 2015 Photolysis of Xe(16) O4 or Xe(18) O4 in noble-gas matrices at 365 nm yielded XeO3 and a new xenon(VIII) oxide, namely, (eta(2) -O2 )XeO3 , which, along with XeO4 , was characterized by matrix-isolation IR spectroscopy and quantum-chemical calculations. Xenon 92-97 cytochrome c oxidase subunit 8A Homo sapiens 98-102 26467531-6 2015 RESULTS: Xenon enhanced the postoperative increase of IL-6 compared to sevoflurane (Xenon: 90.7 versus sevoflurane: 33.7 pg/ml; p = 0.035) and attenuated the increase of IL-10 (Xenon: 127.9 versus sevoflurane: 548.3 pg/ml; p = 0.028). Xenon 9-14 interleukin 6 Homo sapiens 54-58 26467531-6 2015 RESULTS: Xenon enhanced the postoperative increase of IL-6 compared to sevoflurane (Xenon: 90.7 versus sevoflurane: 33.7 pg/ml; p = 0.035) and attenuated the increase of IL-10 (Xenon: 127.9 versus sevoflurane: 548.3 pg/ml; p = 0.028). Xenon 9-14 interleukin 10 Homo sapiens 170-175 26467531-8 2015 While both groups showed an intraoperative increase of the cardioprotective mediators MIF and CXCL12/SDF-1alpha, only MIF levels decreased in the xenon group on the first postoperative day (50.0 ng/ml compared to 23.3 ng/ml; p = 0.012), whereas it remained elevated after sevoflurane anaesthesia (58.3 ng/ml to 53.6 ng/ml). Xenon 146-151 macrophage migration inhibitory factor Homo sapiens 118-121 26922993-4 2016 Xenon stimulates the synthesis of erythropoietin (EPO) by increase of hypoxia inducible factor (HIF). Xenon 0-5 erythropoietin Homo sapiens 34-48 26922993-4 2016 Xenon stimulates the synthesis of erythropoietin (EPO) by increase of hypoxia inducible factor (HIF). Xenon 0-5 erythropoietin Homo sapiens 50-53 26932095-2 2016 The GTS-LHC beam formation has been studied extensively with lead, argon, and xenon beams with varied beam extraction conditions using the ion optical code IBSimu. Xenon 78-83 GTS Homo sapiens 4-7 25844699-0 2015 Xenon Protects Against Septic Acute Kidney Injury via miR-21 Target Signaling Pathway. Xenon 0-5 microRNA 21a Mus musculus 54-60 25844699-10 2015 Furthermore, xenon treatment significantly upregulated the expression of miR-21 in kidney, suppressed proinflammatory factor programmed cell death protein 4 expression and nuclear factor-kappaB activity, and increased interleukin-10 production. Xenon 13-18 microRNA 21a Mus musculus 73-79 25844699-10 2015 Furthermore, xenon treatment significantly upregulated the expression of miR-21 in kidney, suppressed proinflammatory factor programmed cell death protein 4 expression and nuclear factor-kappaB activity, and increased interleukin-10 production. Xenon 13-18 interleukin 10 Mus musculus 218-232 25844699-11 2015 Meanwhile, xenon preconditioning also suppressed the expression of proapoptotic protein phosphatase and tensin homolog deleted on chromosome 10, activating protein kinase B signaling pathway, subsequently increasing the expression of antiapoptotic B-cell lymphoma-2, and inhibiting caspase-3 activity. Xenon 11-16 caspase 3 Mus musculus 282-291 25844699-13 2015 CONCLUSION: Our findings demonstrated that xenon preconditioning protected against lipopolysaccharide-induced acute kidney injury via activation of miR-21 target signaling pathways. Xenon 43-48 microRNA 21a Mus musculus 148-154 25856291-8 2015 Xenon treatment enhanced HIF-1alpha, which attenuated HMGB-1 translocation and NF-kappaB activation in A549 cells with oxidative and inflammatory stress. Xenon 0-5 hypoxia inducible factor 1 subunit alpha Homo sapiens 25-35 25856291-8 2015 Xenon treatment enhanced HIF-1alpha, which attenuated HMGB-1 translocation and NF-kappaB activation in A549 cells with oxidative and inflammatory stress. Xenon 0-5 high mobility group box 1 Homo sapiens 54-60 25856291-8 2015 Xenon treatment enhanced HIF-1alpha, which attenuated HMGB-1 translocation and NF-kappaB activation in A549 cells with oxidative and inflammatory stress. Xenon 0-5 nuclear factor kappa B subunit 1 Homo sapiens 79-88 25856291-9 2015 Xenon treatment enhanced p-mTOR, HIF-1alpha, and Bcl-2 expression and, in turn, promoted cell proliferation in the lung. Xenon 0-5 mechanistic target of rapamycin kinase Homo sapiens 27-31 25856291-9 2015 Xenon treatment enhanced p-mTOR, HIF-1alpha, and Bcl-2 expression and, in turn, promoted cell proliferation in the lung. Xenon 0-5 hypoxia inducible factor 1 subunit alpha Homo sapiens 33-43 25856291-9 2015 Xenon treatment enhanced p-mTOR, HIF-1alpha, and Bcl-2 expression and, in turn, promoted cell proliferation in the lung. Xenon 0-5 BCL2 apoptosis regulator Homo sapiens 49-54 25856291-10 2015 Upon grafting, HMGB-1 translocation from lung epithelial nuclei was reduced; the TLR-4/NF-kappaB pathway was suppressed by xenon treatment; and subsequent tissue injury score (nitrogen vs. xenon: 26 +- 1.8 vs. 10.7 +- 2.6; n = 6) was significantly reduced. Xenon 123-128 toll like receptor 4 Homo sapiens 81-86 25856291-10 2015 Upon grafting, HMGB-1 translocation from lung epithelial nuclei was reduced; the TLR-4/NF-kappaB pathway was suppressed by xenon treatment; and subsequent tissue injury score (nitrogen vs. xenon: 26 +- 1.8 vs. 10.7 +- 2.6; n = 6) was significantly reduced. Xenon 123-128 nuclear factor kappa B subunit 1 Homo sapiens 87-96 25856291-11 2015 CONCLUSION: Xenon treatment confers protection against distant lung injury triggered by renal graft IRI, which is likely through the activation of mTOR-HIF-1alpha pathway and suppression of the HMGB-1 translocation from nuclei to cytoplasm. Xenon 12-17 mechanistic target of rapamycin kinase Homo sapiens 147-151 25856291-11 2015 CONCLUSION: Xenon treatment confers protection against distant lung injury triggered by renal graft IRI, which is likely through the activation of mTOR-HIF-1alpha pathway and suppression of the HMGB-1 translocation from nuclei to cytoplasm. Xenon 12-17 hypoxia inducible factor 1 subunit alpha Homo sapiens 152-162 25856291-11 2015 CONCLUSION: Xenon treatment confers protection against distant lung injury triggered by renal graft IRI, which is likely through the activation of mTOR-HIF-1alpha pathway and suppression of the HMGB-1 translocation from nuclei to cytoplasm. Xenon 12-17 high mobility group box 1 Homo sapiens 194-200 25782754-6 2015 Effects of xenon on HCN channels were verified in human embryonic kidney cells expressing HCN2 channels. Xenon 11-16 hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 Homo sapiens 90-94 25782754-12 2015 CONCLUSIONS: Here, we clearly showed that xenon impairs HCN2 channel function, and this impairment is dependent on intracellular cyclic adenosine monophosphate levels. Xenon 42-47 hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 Homo sapiens 56-60 25034006-2 2014 In this study, we show that nano-hillocks on CaF2 crystal surfaces can be formed by individual impact of medium energy (3 and 5 MeV) highly charged ions (Xe(22+) to Xe(30+)) as well as swift (kinetic energies between 12 and 58 MeV) heavy xenon ions. Xenon 238-243 CCR4-NOT transcription complex subunit 8 Homo sapiens 45-49 25788631-0 2015 Elevated serum concentrations of erythropoietin after xenon anaesthesia in cardiac surgery: secondary analysis of a randomized controlled trial. Xenon 54-59 erythropoietin Homo sapiens 33-47 24618201-1 2015 Variable temperature (-60 to -100 C) studies of ethyldichlorophosphine, CH3CH2PCl2, of the infrared spectra (4000-400 cm(-1)) dissolved in liquid xenon have been carried out. Xenon 147-152 immunoglobulin kappa variable 3-15 Homo sapiens 73-83 25066052-4 2014 The IC50 values of PPIX, PL-C17 micelles, and PL-C17 liposomes toward HeLa cells were 0.53, 5.65, and 12.9muM, respectively, after irradiation with a xenon lamp in the 400-800nm range for 2min. Xenon 150-155 cytokine like 1 Homo sapiens 49-52 25071165-5 2014 Cells expressing the cell surface protein CD14 can be spatially distinguished from control cells with incorporation of as little as 20 nM of the xenon MRI readout unit, cryptophane-A. Xenon 145-150 CD14 molecule Homo sapiens 42-46 25423488-5 2015 The retention times of the xenon in the column are 61.2, 42.2 and 23.5 at the flow rate of 1200, 1600 and 2000 mL min(-1), respectively, but the breakthrough times are 51.4, 38.6 and 35.1 min. Xenon 27-32 CD59 molecule (CD59 blood group) Homo sapiens 114-120 25341786-4 2014 Compounds with oxidation state VIII include several xenon compounds (for example XeO4 and XeO3F2) and the well-characterized species RuO4 and OsO4 (refs 2-4). Xenon 52-57 cytochrome c oxidase subunit 8A Homo sapiens 31-35 24604692-8 2014 RESULTS: We found: 1) an endoscope maximally powered by a xenon or light-emitting diode light source resulted in a rapid temperature elevation up to 46 C within 0.5 to 1 mm from the tip of the endoscope within 30 to 124 seconds, 2) elevated temperatures occurred up to 8 mm from the endoscope tip; and 3) temperature decreased rapidly within 20 to 88 seconds of turning off the light source or applying suction. Xenon 58-63 TOR signaling pathway regulator Homo sapiens 182-185 24604692-8 2014 RESULTS: We found: 1) an endoscope maximally powered by a xenon or light-emitting diode light source resulted in a rapid temperature elevation up to 46 C within 0.5 to 1 mm from the tip of the endoscope within 30 to 124 seconds, 2) elevated temperatures occurred up to 8 mm from the endoscope tip; and 3) temperature decreased rapidly within 20 to 88 seconds of turning off the light source or applying suction. Xenon 58-63 TOR signaling pathway regulator Homo sapiens 293-296 25001620-11 2014 Expression of the pro-angiogenesis factor regulated on activation, normal T cell expressed and secreted (RANTES) was reduced in conditioned medium from xenon-exposed MDA-MB-231 cells compared with cells exposed to either control gas or sevoflurane [mean dot density 2.0 (0.2) compared with 3.0 (0.1) and 3.1 (0.3), respectively (P=0.02)]. Xenon 152-157 C-C motif chemokine ligand 5 Homo sapiens 105-111 24277726-9 2014 Apoptotic cell death was reduced and the ratio of Bcl-2/Bax immunoreactivity increased in xenon-treated rats compared with controls. Xenon 90-95 BCL2, apoptosis regulator Rattus norvegicus 50-55 24277726-9 2014 Apoptotic cell death was reduced and the ratio of Bcl-2/Bax immunoreactivity increased in xenon-treated rats compared with controls. Xenon 90-95 BCL2 associated X, apoptosis regulator Rattus norvegicus 56-59 24861600-2 2014 Since the production of the hypoxia-inducible factor 1alpha (HIF-1alpha) and its downstream effector erythropoietin as well as noradrenalin reuptake inhibition have been found to play key roles in this context, the question arose as to whether the use of xenon is a matter for doping controls and preventive doping research. Xenon 255-260 hypoxia inducible factor 1 subunit alpha Homo sapiens 28-59 24861600-2 2014 Since the production of the hypoxia-inducible factor 1alpha (HIF-1alpha) and its downstream effector erythropoietin as well as noradrenalin reuptake inhibition have been found to play key roles in this context, the question arose as to whether the use of xenon is a matter for doping controls and preventive doping research. Xenon 255-260 hypoxia inducible factor 1 subunit alpha Homo sapiens 61-71 25001620-13 2014 Furthermore, xenon decreased release of the pro-angiogenic factor RANTES from MDA-MB-231 cells. Xenon 13-18 C-C motif chemokine ligand 5 Homo sapiens 66-72 24990797-3 2014 It revealed that glucoses can occupy the side pocket of Mb, and bind closely to one of the xenon cavities in Mb, by hydrogen bonding interactions with two propionate groups of heme as well as surrounding amino acids. Xenon 91-96 myoglobin Homo sapiens 109-111 26036001-0 2014 [Practicing subnarcotic xenon dose inhalation in spa treatment of posttraumatic stress-induced disorders]. Xenon 24-29 surfactant protein A2 Homo sapiens 49-52 24613623-0 2014 Experimental evidence on interaction between xenon and bovine serum albumin. Xenon 45-50 albumin Homo sapiens 62-75 24613623-1 2014 Xenon gas interacts with bovine serum albumin (BSA) dissolved in a physiological buffer solution. Xenon 0-5 albumin Homo sapiens 32-45 24720441-3 2014 FXeGeF and FXeGeF3 are best described by the resonance structures F(-)(Xe-GeF(+)) and F(-)(Xe-GeF3(+)), and feature essentially ionic xenon-fluorine interactions. Xenon 134-139 Rho/Rac guanine nucleotide exchange factor 2 Homo sapiens 3-6 24720441-3 2014 FXeGeF and FXeGeF3 are best described by the resonance structures F(-)(Xe-GeF(+)) and F(-)(Xe-GeF3(+)), and feature essentially ionic xenon-fluorine interactions. Xenon 134-139 Rho guanine nucleotide exchange factor 3 Homo sapiens 14-18 24351506-10 2014 Xenon-preconditioned cells showed a significantly elevated content of VEGF (0.025 +- 0.010 IDV [integrated density values when compared with GAPDH] vs 0.003 +- 0.006 IDV in controls; P = 0.0003). Xenon 0-5 vascular endothelial growth factor A Rattus norvegicus 70-74 24351506-10 2014 Xenon-preconditioned cells showed a significantly elevated content of VEGF (0.025 +- 0.010 IDV [integrated density values when compared with GAPDH] vs 0.003 +- 0.006 IDV in controls; P = 0.0003). Xenon 0-5 glyceraldehyde-3-phosphate dehydrogenase Rattus norvegicus 141-146 24351506-11 2014 The protein expression of HIF-1alpha was increased both by levosimendan (0.563 +- 0.175 IDV vs 0.142 +- 0.042 IDV in controls; P = 0.0289) and by xenon (0.868 +- 0.222 IDV; P < 0.0001) pretreatment. Xenon 146-151 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 26-36 24351506-12 2014 A significant elevation of mRNA expression of iNOS was measureable following preconditioning by xenon but not by the other chosen stimuli. Xenon 96-101 nitric oxide synthase 2 Rattus norvegicus 46-50 24351506-16 2014 In contrast to isoflurane treatment, xenon-induced preconditioning does not lead to an increase in COX-2 gene transcription but to a significant increase in HIF-1alpha and subsequently VEGF. Xenon 37-42 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 157-167 24351506-16 2014 In contrast to isoflurane treatment, xenon-induced preconditioning does not lead to an increase in COX-2 gene transcription but to a significant increase in HIF-1alpha and subsequently VEGF. Xenon 37-42 vascular endothelial growth factor A Rattus norvegicus 185-189 24377428-7 2014 Immunochemical induction of c-fos in the cortex was significantly suppressed (p < 0.01) after administration of xenon. Xenon 115-120 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 28-33 24377428-8 2014 The molecular analysis revealed significant effects of N2O and xenon administration on c-fos and MMP-9 expression. Xenon 63-68 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 87-92 24377428-8 2014 The molecular analysis revealed significant effects of N2O and xenon administration on c-fos and MMP-9 expression. Xenon 63-68 matrix metallopeptidase 9 Rattus norvegicus 97-102 23867231-10 2013 Xenon inhibits N-methyl-D-aspartate receptors and activates TREK-1 channels, whereas argon, krypton, neon, and helium have no effect on these ion channels. Xenon 0-5 potassium channel, subfamily K, member 2 Mus musculus 60-66 24025645-4 2014 Exposure to xenon enhanced the expression of insulin growth factor-1 (IGF-1) and its receptor in human proximal tubular (HK-2) cells, which, in turn, increased cell proliferation. Xenon 12-17 insulin like growth factor 1 Homo sapiens 45-68 24025645-4 2014 Exposure to xenon enhanced the expression of insulin growth factor-1 (IGF-1) and its receptor in human proximal tubular (HK-2) cells, which, in turn, increased cell proliferation. Xenon 12-17 insulin like growth factor 1 Homo sapiens 70-75 24025645-6 2014 The xenon-induced HK-2 cell proliferation was abolished by blocking the IGF-1 receptor, mTOR, and HIF-1alpha individually. Xenon 4-9 insulin-like growth factor 1 receptor Rattus norvegicus 72-86 24025645-6 2014 The xenon-induced HK-2 cell proliferation was abolished by blocking the IGF-1 receptor, mTOR, and HIF-1alpha individually. Xenon 4-9 mechanistic target of rapamycin kinase Rattus norvegicus 88-92 24025645-6 2014 The xenon-induced HK-2 cell proliferation was abolished by blocking the IGF-1 receptor, mTOR, and HIF-1alpha individually. Xenon 4-9 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 98-108 24223728-4 2013 Three internal hydrophobic cavities were located by xenon trapping experiments on FGAR-AT crystals and further, these cavities were perturbed via site-directed mutagenesis. Xenon 52-57 phosphoribosylformylglycinamidine synthase Homo sapiens 82-89 23899927-4 2013 The effect of hypothermia (HT) and Xenon (Xe) on PRx was studied. Xenon 35-40 periaxin Sus scrofa 49-52 23899927-4 2013 The effect of hypothermia (HT) and Xenon (Xe) on PRx was studied. Xenon 35-37 periaxin Sus scrofa 49-52 23899927-11 2013 Xenon abolished the secondary PRx peak, increased (mean (95% confidence interval (CI)) MABP (6.5 (3.8, 9.4) mm Hg) and cerebral perfusion pressure (5.9 (2.9, 8.9) mm Hg) and preserved the PRx (regression coefficient, -0.098 (95% CI (-0.18, -0.01)), independent of the insult severity. Xenon 0-5 periaxin Sus scrofa 30-33 23899927-11 2013 Xenon abolished the secondary PRx peak, increased (mean (95% confidence interval (CI)) MABP (6.5 (3.8, 9.4) mm Hg) and cerebral perfusion pressure (5.9 (2.9, 8.9) mm Hg) and preserved the PRx (regression coefficient, -0.098 (95% CI (-0.18, -0.01)), independent of the insult severity. Xenon 0-5 periaxin Sus scrofa 188-191 22425822-13 2012 However, only the combination of mild therapeutic hypothermia and xenon resulted in reduced astrogliosis in the CA1 sector and diminished microgliosis and perivascular inflammation in the putamen. Xenon 66-71 carbonic anhydrase 1 Sus scrofa 112-115 23907115-7 2013 In line with this notion, argon and xenon inhibited the apoptotic activation of caspase-3, as determined by immunofluorescence microscopy coupled to automated image analysis. Xenon 36-41 caspase 3 Homo sapiens 80-89 23591069-6 2013 RESULTS: Xenon caused death of hippocampal neurons in CA1, CA3, and dentate regions after 1 and 2 MAC exposures, but not at 0.75 MAC. Xenon 9-14 carbonic anhydrase 1 Rattus norvegicus 54-57 23591069-6 2013 RESULTS: Xenon caused death of hippocampal neurons in CA1, CA3, and dentate regions after 1 and 2 MAC exposures, but not at 0.75 MAC. Xenon 9-14 carbonic anhydrase 3 Rattus norvegicus 59-62 23710625-4 2013 Xenon treatment prior to or after hypothermia-hypoxia challenge stabilized the HK-2 cellular structure, diminished cytoplasmic translocation of high-mobility group box (HMGB) 1 and suppressed NF-kappaB activation. Xenon 0-5 high mobility group box 1 Rattus norvegicus 144-176 23710625-5 2013 In the syngeneic Lewis-to-Lewis rat model of kidney transplantation, xenon exposure to donors before graft retrieval or to recipients after engraftment decreased caspase-3 expression, localized HMGB-1 within nuclei and prevented TLR-4/NF-kappaB activation in tubular cells; serum pro-inflammatory cytokines IL-1beta, IL-6 and TNF-alpha were reduced and renal function was preserved. Xenon 69-74 caspase 3 Rattus norvegicus 162-171 23710625-5 2013 In the syngeneic Lewis-to-Lewis rat model of kidney transplantation, xenon exposure to donors before graft retrieval or to recipients after engraftment decreased caspase-3 expression, localized HMGB-1 within nuclei and prevented TLR-4/NF-kappaB activation in tubular cells; serum pro-inflammatory cytokines IL-1beta, IL-6 and TNF-alpha were reduced and renal function was preserved. Xenon 69-74 high mobility group box 1 Rattus norvegicus 194-200 23710625-5 2013 In the syngeneic Lewis-to-Lewis rat model of kidney transplantation, xenon exposure to donors before graft retrieval or to recipients after engraftment decreased caspase-3 expression, localized HMGB-1 within nuclei and prevented TLR-4/NF-kappaB activation in tubular cells; serum pro-inflammatory cytokines IL-1beta, IL-6 and TNF-alpha were reduced and renal function was preserved. Xenon 69-74 toll-like receptor 4 Rattus norvegicus 229-234 23710625-5 2013 In the syngeneic Lewis-to-Lewis rat model of kidney transplantation, xenon exposure to donors before graft retrieval or to recipients after engraftment decreased caspase-3 expression, localized HMGB-1 within nuclei and prevented TLR-4/NF-kappaB activation in tubular cells; serum pro-inflammatory cytokines IL-1beta, IL-6 and TNF-alpha were reduced and renal function was preserved. Xenon 69-74 interleukin 1 beta Rattus norvegicus 307-315 23710625-5 2013 In the syngeneic Lewis-to-Lewis rat model of kidney transplantation, xenon exposure to donors before graft retrieval or to recipients after engraftment decreased caspase-3 expression, localized HMGB-1 within nuclei and prevented TLR-4/NF-kappaB activation in tubular cells; serum pro-inflammatory cytokines IL-1beta, IL-6 and TNF-alpha were reduced and renal function was preserved. Xenon 69-74 interleukin 6 Rattus norvegicus 317-321 23710625-5 2013 In the syngeneic Lewis-to-Lewis rat model of kidney transplantation, xenon exposure to donors before graft retrieval or to recipients after engraftment decreased caspase-3 expression, localized HMGB-1 within nuclei and prevented TLR-4/NF-kappaB activation in tubular cells; serum pro-inflammatory cytokines IL-1beta, IL-6 and TNF-alpha were reduced and renal function was preserved. Xenon 69-74 tumor necrosis factor Rattus norvegicus 326-335 23710625-7 2013 Xenon induced cell survival or graft functional recovery was abolished by HIF-1alpha siRNA. Xenon 0-5 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 74-84 23736625-1 2013 We demonstrate that filling a hollow-core photonic-bandgap fiber with supercritical xenon creates a medium with a controllable density up to several hundred times that at STP, while working at room temperature. Xenon 84-89 thyroid hormone receptor interactor 10 Homo sapiens 171-174 23364599-9 2013 Xenon in contrast to isoflurane or ketamine anesthetized animals demonstrated a lower remodeling index (0.7 +- 0.1 vs. 0.9 +- 0.3 and 1.0 +- 0.3g/ml), better ejection fraction (62 +- 9 vs. 49 +- 7 and 35 +- 6%), and reduced expression of beta-myosin heavy chain and periostin. Xenon 0-5 myosin heavy chain 7 Rattus norvegicus 238-261 23364599-9 2013 Xenon in contrast to isoflurane or ketamine anesthetized animals demonstrated a lower remodeling index (0.7 +- 0.1 vs. 0.9 +- 0.3 and 1.0 +- 0.3g/ml), better ejection fraction (62 +- 9 vs. 49 +- 7 and 35 +- 6%), and reduced expression of beta-myosin heavy chain and periostin. Xenon 0-5 periostin Rattus norvegicus 266-275 23540943-0 2013 [Li(XeF2)n](AF6) (A = P, As, Ru, Ir), the first xenon(II) compounds of lithium. Xenon 48-53 afadin, adherens junction formation factor Homo sapiens 12-15 24169702-1 2013 Xenon and Iridiumhexafluoride react at temperatures above room temperature forming XeF+IrF6-. Xenon 0-5 interferon regulatory factor 6 Homo sapiens 87-91 22902581-6 2012 Both E-AG and E-SG conformers could be trapped from room temperature gas phase in low temperature argon and xenon matrices. Xenon 108-113 potassium voltage-gated channel subfamily H member 1 Homo sapiens 5-9 22902581-6 2012 Both E-AG and E-SG conformers could be trapped from room temperature gas phase in low temperature argon and xenon matrices. Xenon 108-113 sarcoglycan epsilon Homo sapiens 14-18 22627268-4 2012 In addition, xenon hydrate involving 15-hedral cages has been synthesized and named an hsI hydrate. Xenon 13-18 aldo-keto reductase family 1 member B10 Homo sapiens 87-90 22610177-13 2012 In the nondirectly injured hemisphere, argon, helium, and xenon increased the expression of Bcl-2, whereas helium and xenon increased Bcl-xL. Xenon 58-63 BCL2, apoptosis regulator Rattus norvegicus 92-97 22610177-13 2012 In the nondirectly injured hemisphere, argon, helium, and xenon increased the expression of Bcl-2, whereas helium and xenon increased Bcl-xL. Xenon 118-123 Bcl2-like 1 Rattus norvegicus 134-140 23759444-4 2013 Xenon exposure enhanced the expression of heat-shock protein 70 (HSP-70) and heme oxygenase 1 (HO-1) and promoted cell survival after hypothermia-hypoxia insult in human proximal tubular (HK-2) cells, which was abolished by HSP-70 or HO-1 siRNA. Xenon 0-5 heat shock protein family A (Hsp70) member 4 Homo sapiens 42-63 23759444-4 2013 Xenon exposure enhanced the expression of heat-shock protein 70 (HSP-70) and heme oxygenase 1 (HO-1) and promoted cell survival after hypothermia-hypoxia insult in human proximal tubular (HK-2) cells, which was abolished by HSP-70 or HO-1 siRNA. Xenon 0-5 heat shock protein family A (Hsp70) member 4 Homo sapiens 65-71 23759444-4 2013 Xenon exposure enhanced the expression of heat-shock protein 70 (HSP-70) and heme oxygenase 1 (HO-1) and promoted cell survival after hypothermia-hypoxia insult in human proximal tubular (HK-2) cells, which was abolished by HSP-70 or HO-1 siRNA. Xenon 0-5 heme oxygenase 1 Homo sapiens 77-93 23759444-4 2013 Xenon exposure enhanced the expression of heat-shock protein 70 (HSP-70) and heme oxygenase 1 (HO-1) and promoted cell survival after hypothermia-hypoxia insult in human proximal tubular (HK-2) cells, which was abolished by HSP-70 or HO-1 siRNA. Xenon 0-5 heme oxygenase 1 Homo sapiens 95-99 23759444-4 2013 Xenon exposure enhanced the expression of heat-shock protein 70 (HSP-70) and heme oxygenase 1 (HO-1) and promoted cell survival after hypothermia-hypoxia insult in human proximal tubular (HK-2) cells, which was abolished by HSP-70 or HO-1 siRNA. Xenon 0-5 heat shock protein family A (Hsp70) member 4 Homo sapiens 224-230 23759444-4 2013 Xenon exposure enhanced the expression of heat-shock protein 70 (HSP-70) and heme oxygenase 1 (HO-1) and promoted cell survival after hypothermia-hypoxia insult in human proximal tubular (HK-2) cells, which was abolished by HSP-70 or HO-1 siRNA. Xenon 0-5 heme oxygenase 1 Homo sapiens 234-238 23981341-0 2013 Propagation of dynamic nuclear polarization across the xenon cluster boundaries: elucidation of the spin-diffusion bottleneck. Xenon 55-60 spindlin 1 Homo sapiens 100-104 24245210-4 2013 Photocatalytic ability examination of the FT1 and FT4 core-shell particles was carried out in Rhodamine B (RhB) solutions illuminated under Xe light in a photochemical reactor. Xenon 140-142 AKT interacting protein Homo sapiens 42-45 23681145-0 2013 miR-21 contributes to xenon-conferred amelioration of renal ischemia-reperfusion injury in mice. Xenon 22-27 microRNA 21a Mus musculus 0-6 23681145-4 2013 The role of microRNA, miR-21, in renal protection conferred by the delayed xenon preconditioning was examined using in vivo knockdown of miR-21 and analysis of miR-21 target pathways. Xenon 75-80 microRNA 21a Mus musculus 22-28 23681145-6 2013 Xenon preconditioning significantly increased the expression of miR-21 in the mouse kidney. Xenon 0-5 microRNA 21a Mus musculus 64-70 23681145-7 2013 A locked nucleic acid-modified anti-miR-21, given before xenon preconditioning, knocked down miR-21 effectively, and exacerbated subsequent renal ischemia-reperfusion injury. Xenon 57-62 microRNA 21a Mus musculus 36-42 23681145-10 2013 In addition, xenon preconditioning up-regulated hypoxia-inducible factor-1alpha and its downstream effector vascular endothelial growth factor in a time-dependent manner. Xenon 13-18 hypoxia inducible factor 1, alpha subunit Mus musculus 48-79 23681145-12 2013 CONCLUSIONS: These results indicate that miR-21 contributes to the renoprotective effect of xenon preconditioning. Xenon 92-97 microRNA 21a Mus musculus 41-47 22634870-8 2012 CONCLUSIONS: These findings confirm xenon binds to the glycine site of the GluN1 subunit of the NMDA receptor and indicate that interactions between xenon and the aromatic ring of the phenylalanine 758 residue are important for xenon binding. Xenon 36-41 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 75-80 21697446-2 2011 We used whole cell voltage clamp to show that the Kv7 blockers linopirdine and XE-991 blocked a current with similar kinetics to the current remaining after combined block of Kv1 and Kv2 channels. Xenon 79-81 potassium voltage-gated channel subfamily A member 5 Rattus norvegicus 175-178 22293720-4 2012 In hippocampal brain slices, the authors investigated in area CA1 whether xenon affects LTP, NMDA receptor-mediated neurotransmission, and intracellular calcium concentrations. Xenon 74-79 carbonic anhydrase 1 Mus musculus 62-65 22761550-10 2012 This supports the thesis that xenon mediates its effects not only via an antagonism at the NMDA-receptor. Xenon 30-35 NMDA receptor 1 Drosophila melanogaster 91-104 21967761-5 2011 The capabilities of MDpocket are illustrated for three relevant cases: (i) the detection of transient subpockets using an ensemble of crystal structures of HSP90; (ii) the detection of known xenon binding sites and migration pathways in myoglobin; and (iii) the identification of suitable pockets for molecular docking in P38 Map kinase. Xenon 191-196 heat shock protein 90 alpha family class A member 1 Homo sapiens 156-161 21967761-5 2011 The capabilities of MDpocket are illustrated for three relevant cases: (i) the detection of transient subpockets using an ensemble of crystal structures of HSP90; (ii) the detection of known xenon binding sites and migration pathways in myoglobin; and (iii) the identification of suitable pockets for molecular docking in P38 Map kinase. Xenon 191-196 mitogen-activated protein kinase 14 Homo sapiens 322-336 21952256-3 2011 However, a recent study has shown that xenon interacts with tissue-type plasminogen activator (tPA), a well-recognized approved therapy of acute ischemic stroke. Xenon 39-44 plasminogen activator, tissue type Rattus norvegicus 60-93 21952256-3 2011 However, a recent study has shown that xenon interacts with tissue-type plasminogen activator (tPA), a well-recognized approved therapy of acute ischemic stroke. Xenon 39-44 plasminogen activator, tissue type Rattus norvegicus 95-98 21952256-4 2011 Although intraischemic xenon inhibits tPA-induced thrombolysis and subsequent reduction of brain damage, postischemic xenon virtually suppresses both ischemic brain damage and tPA-induced brain hemorrhages and disruption of the blood-brain barrier. Xenon 23-28 plasminogen activator, tissue type Rattus norvegicus 38-41 21952256-4 2011 Although intraischemic xenon inhibits tPA-induced thrombolysis and subsequent reduction of brain damage, postischemic xenon virtually suppresses both ischemic brain damage and tPA-induced brain hemorrhages and disruption of the blood-brain barrier. Xenon 118-123 plasminogen activator, tissue type Rattus norvegicus 176-179 21559793-0 2012 Xenon anesthesia reduces TNFalpha and IL10 in bariatric patients. Xenon 0-5 tumor necrosis factor Homo sapiens 25-33 21559793-0 2012 Xenon anesthesia reduces TNFalpha and IL10 in bariatric patients. Xenon 0-5 interleukin 10 Homo sapiens 38-42 21559793-11 2012 CONCLUSIONS: Xenon anesthesia seems able to inhibit postoperative proinflammatory cytokine imbalance in morbidly obese patients undergoing Roux-en-Y laparoscopic gastric bypass; the reduced DeltaTNFalpha at T1 and the reduced global exposition to TNFalpha in the XE group may explain the reduced DeltaIL10 at T1 and T2. Xenon 13-18 tumor necrosis factor Homo sapiens 195-203 26592871-0 2012 Fully Relativistic Calculations of Faraday and Nuclear Spin-Induced Optical Rotation in Xenon. Xenon 88-93 spindlin 1 Homo sapiens 55-59 21952256-7 2011 RESULTS: The authors demonstrate nitrous oxide is a tPA inhibitor, intraischemic nitrous oxide dose-dependently inhibits tPA-induced thrombolysis and subsequent reduction of ischemic brain damage, and postischemic nitrous oxide reduces ischemic brain damage, but in contrast with xenon, it increases brain hemorrhages and disruption of the blood-brain barrier. Xenon 280-285 plasminogen activator, tissue type Rattus norvegicus 52-55 21952256-7 2011 RESULTS: The authors demonstrate nitrous oxide is a tPA inhibitor, intraischemic nitrous oxide dose-dependently inhibits tPA-induced thrombolysis and subsequent reduction of ischemic brain damage, and postischemic nitrous oxide reduces ischemic brain damage, but in contrast with xenon, it increases brain hemorrhages and disruption of the blood-brain barrier. Xenon 280-285 plasminogen activator, tissue type Rattus norvegicus 121-124 21697446-2 2011 We used whole cell voltage clamp to show that the Kv7 blockers linopirdine and XE-991 blocked a current with similar kinetics to the current remaining after combined block of Kv1 and Kv2 channels. Xenon 79-81 potassium voltage-gated channel subfamily A member 6 Rattus norvegicus 183-186 20680516-0 2011 Xenon enhances LPS-induced IL-1beta expression in microglia via the extracellular signal-regulated kinase 1/2 pathway. Xenon 0-5 interleukin 1 beta Mus musculus 27-35 20680516-0 2011 Xenon enhances LPS-induced IL-1beta expression in microglia via the extracellular signal-regulated kinase 1/2 pathway. Xenon 0-5 mitogen-activated protein kinase 3 Mus musculus 68-107 20680516-6 2011 Xenon significantly enhanced LPS-mediated IL-1beta expression. Xenon 0-5 interleukin 1 beta Mus musculus 42-50 20680516-7 2011 ERK 1/2 phosphorylation was observed after xenon or LPS treatment which was inhibited by the use of the MEK inhibitor U0126. Xenon 43-48 mitogen-activated protein kinase 3 Mus musculus 0-7 20680516-7 2011 ERK 1/2 phosphorylation was observed after xenon or LPS treatment which was inhibited by the use of the MEK inhibitor U0126. Xenon 43-48 midkine Mus musculus 104-107 20680516-8 2011 Xenon and LPS in combination superimposed individual effects on ERK 1/2 activation. Xenon 0-5 mitogen-activated protein kinase 3 Mus musculus 64-71 20680516-9 2011 Xenon decreased cellular phosphatase activity in microglia by 20% and inhibited dephosphorylation of ERK 1/2 up to 1 h. The blocking of ERK 1/2 reduced IL-1beta expression in xenon and LPS-treated cells to a level obtained by LPS alone. Xenon 0-5 mitogen-activated protein kinase 3 Mus musculus 101-108 20680516-9 2011 Xenon decreased cellular phosphatase activity in microglia by 20% and inhibited dephosphorylation of ERK 1/2 up to 1 h. The blocking of ERK 1/2 reduced IL-1beta expression in xenon and LPS-treated cells to a level obtained by LPS alone. Xenon 0-5 mitogen-activated protein kinase 3 Mus musculus 136-143 20680516-9 2011 Xenon decreased cellular phosphatase activity in microglia by 20% and inhibited dephosphorylation of ERK 1/2 up to 1 h. The blocking of ERK 1/2 reduced IL-1beta expression in xenon and LPS-treated cells to a level obtained by LPS alone. Xenon 0-5 interleukin 1 beta Mus musculus 152-160 20680516-9 2011 Xenon decreased cellular phosphatase activity in microglia by 20% and inhibited dephosphorylation of ERK 1/2 up to 1 h. The blocking of ERK 1/2 reduced IL-1beta expression in xenon and LPS-treated cells to a level obtained by LPS alone. Xenon 175-180 mitogen-activated protein kinase 3 Mus musculus 136-143 20680516-9 2011 Xenon decreased cellular phosphatase activity in microglia by 20% and inhibited dephosphorylation of ERK 1/2 up to 1 h. The blocking of ERK 1/2 reduced IL-1beta expression in xenon and LPS-treated cells to a level obtained by LPS alone. Xenon 175-180 interleukin 1 beta Mus musculus 152-160 20680516-10 2011 In conclusion, xenon enhanced LPS-induced IL-1beta expression in microglia by activation of ERK 1/2 signalling. Xenon 15-20 interleukin 1 beta Mus musculus 42-50 20680516-10 2011 In conclusion, xenon enhanced LPS-induced IL-1beta expression in microglia by activation of ERK 1/2 signalling. Xenon 15-20 mitogen-activated protein kinase 3 Mus musculus 92-99 21056583-8 2011 SIGNIFICANCE: Xenon substantially reduces the activity of TRPV1 in response to noxious stimulation by the specific TRPV1 agonist, capsaicin, suggesting a possible role for xenon as an adjunct analgesic where hTRPV1 is an active contributor to the excitation of primary afferents which initiates the pain sensation. Xenon 14-19 transient receptor potential cation channel subfamily V member 1 Homo sapiens 58-63 21651960-1 2011 To investigate whether the xenon-induced inhibition of the transient receptor potential vanilloid type 1 (TRPV1) ion channel in rat dorsal root ganglion (DRG) neurons reduces nociceptive processing, we examined the effect of xenon in reducing the release of calcitonin gene-related peptide (CGRP) from those neurons. Xenon 27-32 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 59-104 21651960-1 2011 To investigate whether the xenon-induced inhibition of the transient receptor potential vanilloid type 1 (TRPV1) ion channel in rat dorsal root ganglion (DRG) neurons reduces nociceptive processing, we examined the effect of xenon in reducing the release of calcitonin gene-related peptide (CGRP) from those neurons. Xenon 27-32 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 106-111 21651960-1 2011 To investigate whether the xenon-induced inhibition of the transient receptor potential vanilloid type 1 (TRPV1) ion channel in rat dorsal root ganglion (DRG) neurons reduces nociceptive processing, we examined the effect of xenon in reducing the release of calcitonin gene-related peptide (CGRP) from those neurons. Xenon 27-32 calcitonin-related polypeptide alpha Rattus norvegicus 258-289 21651960-1 2011 To investigate whether the xenon-induced inhibition of the transient receptor potential vanilloid type 1 (TRPV1) ion channel in rat dorsal root ganglion (DRG) neurons reduces nociceptive processing, we examined the effect of xenon in reducing the release of calcitonin gene-related peptide (CGRP) from those neurons. Xenon 27-32 calcitonin-related polypeptide alpha Rattus norvegicus 291-295 21651960-3 2011 This finding suggests that xenon acts on several molecular targets on nociceptive primary sensory neurons, and that xenon"s action on one, or more, of those targets serves to offset the inhibitory, pro-analgesic, effect of xenon on TRPV1. Xenon 116-121 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 232-237 21651960-3 2011 This finding suggests that xenon acts on several molecular targets on nociceptive primary sensory neurons, and that xenon"s action on one, or more, of those targets serves to offset the inhibitory, pro-analgesic, effect of xenon on TRPV1. Xenon 116-121 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 232-237 21539397-4 2011 It appears that the pore system of DUT-8(Ni) takes up xenon until a liquid-like state is reached. Xenon 54-59 deoxyuridine triphosphatase Homo sapiens 35-38 21539397-5 2011 Deeper insight into the interactions between the host DUT-8(Ni) and the guest atom xenon is gained from ab initio molecular dynamics (MD) simulations. Xenon 83-88 deoxyuridine triphosphatase Homo sapiens 54-57 21617619-7 2011 RESULTS: Compared to control air-breathing animals, xenon-breathing rats exhibited a 0.7-fold decrease in Akt mRNA expression (P<0.01) and a 1.6-fold increase in JNKK1 mRNA levels (P<0.05). Xenon 52-57 AKT serine/threonine kinase 1 Rattus norvegicus 106-109 21617619-8 2011 CONCLUSION: The concomitant decrease in the Akt mRNA expression level and increase in the JNKK1 mRNA transcript level provide evidence that xenon has a neuroapoptotic effect in the developing rodent forebrain. Xenon 140-145 AKT serine/threonine kinase 1 Rattus norvegicus 44-47 21503281-2 2011 Among them, PEV and AEV can bind with calf thymus DNA mainly through intercalation and groove-binding modes, and both of them can be observed to photocleave plasmid pBR 322 DNA significantly under irradiation with a xenon arc lamp. Xenon 216-221 translocator protein Bos taurus 165-168 21056583-0 2011 Xenon reduces activation of transient receptor potential vanilloid type 1 (TRPV1) in rat dorsal root ganglion cells and in human TRPV1-expressing HEK293 cells. Xenon 0-5 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 28-73 21056583-0 2011 Xenon reduces activation of transient receptor potential vanilloid type 1 (TRPV1) in rat dorsal root ganglion cells and in human TRPV1-expressing HEK293 cells. Xenon 0-5 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 75-80 21056583-0 2011 Xenon reduces activation of transient receptor potential vanilloid type 1 (TRPV1) in rat dorsal root ganglion cells and in human TRPV1-expressing HEK293 cells. Xenon 0-5 transient receptor potential cation channel subfamily V member 1 Homo sapiens 129-134 21056583-2 2011 Our aim was to examine whether xenon may mediate its analgesic effect, in part, through reducing the activity of transient receptor potential vanilloid type 1 (TRPV1), a receptor known to be involved in certain inflammatory pain conditions. Xenon 31-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 113-158 21056583-2 2011 Our aim was to examine whether xenon may mediate its analgesic effect, in part, through reducing the activity of transient receptor potential vanilloid type 1 (TRPV1), a receptor known to be involved in certain inflammatory pain conditions. Xenon 31-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 160-165 21056583-4 2011 We also examined xenon"s effect on the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the rat spinal dorsal horn evoked by hind-paw injection of capsaicin. Xenon 17-22 mitogen activated protein kinase 3 Rattus norvegicus 58-99 21056583-4 2011 We also examined xenon"s effect on the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the rat spinal dorsal horn evoked by hind-paw injection of capsaicin. Xenon 17-22 mitogen activated protein kinase 3 Rattus norvegicus 101-107 21056583-5 2011 KEY FINDINGS: Xenon (75%) reduced the number of primary sensory neurons responding to the TRPV1 agonist, capsaicin (100 nM-1 muM) by ~25% to ~50%. Xenon 14-19 transient receptor potential cation channel subfamily V member 1 Homo sapiens 90-95 21056583-6 2011 Xenon reduced the number of heterologously-expressed hTRPV1 activated by 300 nM capsaicin by ~50%. Xenon 0-5 transient receptor potential cation channel subfamily V member 1 Homo sapiens 53-59 21056583-7 2011 Xenon (80%) reduced by ~40% the number of phosphorylated ERK1/2-expressing neurons in rat spinal dorsal horn resulting from hind-paw capsaicin injection. Xenon 0-5 mitogen activated protein kinase 3 Rattus norvegicus 57-63 21056583-8 2011 SIGNIFICANCE: Xenon substantially reduces the activity of TRPV1 in response to noxious stimulation by the specific TRPV1 agonist, capsaicin, suggesting a possible role for xenon as an adjunct analgesic where hTRPV1 is an active contributor to the excitation of primary afferents which initiates the pain sensation. Xenon 14-19 transient receptor potential cation channel subfamily V member 1 Homo sapiens 115-120 21056583-8 2011 SIGNIFICANCE: Xenon substantially reduces the activity of TRPV1 in response to noxious stimulation by the specific TRPV1 agonist, capsaicin, suggesting a possible role for xenon as an adjunct analgesic where hTRPV1 is an active contributor to the excitation of primary afferents which initiates the pain sensation. Xenon 14-19 transient receptor potential cation channel subfamily V member 1 Homo sapiens 208-214 21056583-8 2011 SIGNIFICANCE: Xenon substantially reduces the activity of TRPV1 in response to noxious stimulation by the specific TRPV1 agonist, capsaicin, suggesting a possible role for xenon as an adjunct analgesic where hTRPV1 is an active contributor to the excitation of primary afferents which initiates the pain sensation. Xenon 172-177 transient receptor potential cation channel subfamily V member 1 Homo sapiens 58-63 21056583-8 2011 SIGNIFICANCE: Xenon substantially reduces the activity of TRPV1 in response to noxious stimulation by the specific TRPV1 agonist, capsaicin, suggesting a possible role for xenon as an adjunct analgesic where hTRPV1 is an active contributor to the excitation of primary afferents which initiates the pain sensation. Xenon 172-177 transient receptor potential cation channel subfamily V member 1 Homo sapiens 115-120 20472713-12 2010 Xenon caused an increased expression of p-Akt, HIF-1alpha and Bcl-2, while the other noble gases did not modify protein expression. Xenon 0-5 AKT serine/threonine kinase 1 Homo sapiens 42-45 22470401-10 2011 In addition, kidneys stored with argon, and to a lesser extent those stored with xenon, displayed preserved renal architecture as well as higher CD-10 and little active caspase-3 expression compared to other groups. Xenon 81-86 membrane metallo-endopeptidase Rattus norvegicus 145-150 22073162-2 2011 We hypothesized that xenon pretreatment prevents POCD by suppressing the systemic inflammatory response or through an associated protective signaling pathway involving heat shock protein 72 (Hsp72) and PI3-kinase. Xenon 21-26 heat shock protein 1A Mus musculus 168-189 22073162-2 2011 We hypothesized that xenon pretreatment prevents POCD by suppressing the systemic inflammatory response or through an associated protective signaling pathway involving heat shock protein 72 (Hsp72) and PI3-kinase. Xenon 21-26 heat shock protein 1A Mus musculus 191-196 22073162-8 2011 Xenon pretreatment modulated the expression of Hsp72 (P = 0.054) but had no significant effect on PI3-kinase (P = 0.54), when compared to control. Xenon 0-5 heat shock protein 1A Mus musculus 47-52 22073162-9 2011 Xenon pretreatment also reduced the plasma level increase of IL-1beta induced by surgery (P = 0.028). Xenon 0-5 interleukin 1 beta Mus musculus 61-69 21789173-1 2011 In hyperpolarized xenon magnetic resonance imaging (HP (129)Xe MRI), the inhaled spin-1/2 isotope of xenon gas is used to generate the MR signal. Xenon 18-23 spindlin 1 Rattus norvegicus 81-87 21789173-1 2011 In hyperpolarized xenon magnetic resonance imaging (HP (129)Xe MRI), the inhaled spin-1/2 isotope of xenon gas is used to generate the MR signal. Xenon 101-106 spindlin 1 Rattus norvegicus 81-87 20613483-10 2010 Xenon pretreatment increased Bcl-2 expression and decreased both cytochrome C release and P53 expression; conversely, the opposite was evident after hypoxic pretreatment. Xenon 0-5 BCL2, apoptosis regulator Rattus norvegicus 29-34 20613483-10 2010 Xenon pretreatment increased Bcl-2 expression and decreased both cytochrome C release and P53 expression; conversely, the opposite was evident after hypoxic pretreatment. Xenon 0-5 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 90-93 20472713-12 2010 Xenon caused an increased expression of p-Akt, HIF-1alpha and Bcl-2, while the other noble gases did not modify protein expression. Xenon 0-5 hypoxia inducible factor 1 subunit alpha Homo sapiens 47-57 20472713-12 2010 Xenon caused an increased expression of p-Akt, HIF-1alpha and Bcl-2, while the other noble gases did not modify protein expression. Xenon 0-5 BCL2 apoptosis regulator Homo sapiens 62-67 20392049-0 2010 A xenon-based molecular sensor assembled on an MS2 viral capsid scaffold. Xenon 2-7 MS2 Homo sapiens 47-50 20392049-4 2010 We have incorporated approximately 125 xenon sensor molecules in the interior of an MS2 viral capsid, conferring multivalency and other properties of the viral capsid to the sensor molecule. Xenon 39-44 MS2 Homo sapiens 84-87 19839950-12 2010 Upregulation of BNP mRNA expression was impeded in the remote area of the LV by both isoflurane and xenon. Xenon 100-105 natriuretic peptide B Homo sapiens 16-19 20237695-2 2010 We examined xenon bound on myoglobin and on a fragment of ammonium transporter. Xenon 12-17 myoglobin Homo sapiens 27-36 19908166-10 2010 Both NIRS and DCS distinguished the effects of xenon inhalation on CBF, which varied among the patients. Xenon 47-52 CCAAT/enhancer binding protein zeta Rattus norvegicus 14-17 20087367-0 2010 Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke. Xenon 0-5 plasminogen activator, tissue type Rattus norvegicus 25-53 20087367-4 2010 Because the active site of serine proteases is structurally conserved, we have hypothesized and investigated whether xenon may alter the catalytic efficiency of tissue-type plasminogen activator (tPA), a serine protease that is the only approved therapy for acute ischemic stroke today. Xenon 117-122 plasminogen activator, tissue type Rattus norvegicus 161-200 19144758-2 2009 Here, we show that preconditioning with the anesthetic gas xenon activates hypoxia-inducible factor 1alpha (HIF-1alpha) and its downstream effectors erythropoietin and vascular endothelial growth factor in a time-dependent manner in the kidneys of adult mice. Xenon 59-64 hypoxia inducible factor 1, alpha subunit Mus musculus 75-106 20124979-2 2010 A small number of molecular targets for xenon have been identified, the N-methyl-D-aspartate (NMDA) receptor, the two-pore-domain potassium channel TREK-1, and the adenosine triphosphate-sensitive potassium channel (KATP). Xenon 40-45 potassium channel, subfamily K, member 2 Mus musculus 148-154 19686722-0 2009 The xenon-mediated antagonism against the NMDA receptor is non-selective for receptors containing either NR2A or NR2B subunits in the mouse amygdala. Xenon 4-9 glutamate receptor, ionotropic, NMDA2A (epsilon 1) Mus musculus 105-109 19686722-0 2009 The xenon-mediated antagonism against the NMDA receptor is non-selective for receptors containing either NR2A or NR2B subunits in the mouse amygdala. Xenon 4-9 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 113-117 19686722-7 2009 These results provide evidence, that the Xe-induced antagonism against NMDA receptors is non-selective against NR2A- or NR2B-containing receptors. Xenon 41-43 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 120-124 20179498-5 2010 RESULTS: Xenon, in contrast to classic KATP channel openers, acted directly on the Kir6.2 subunit of the channel. Xenon 9-14 potassium inwardly rectifying channel subfamily J member 11 Homo sapiens 83-89 20179498-9 2010 CONCLUSIONS: Xenon represents a novel KATP channel opener that increases KATP currents independently of the sulfonylurea receptor-1 subunit by reducing ATP inhibition of the channel. Xenon 13-18 ATP binding cassette subfamily C member 8 Homo sapiens 108-131 19805177-2 2009 We demonstrate hyperpolarized xenon signal amplification by gas extraction (Hyper-SAGE) in both NMR spectra and magnetic resonance images with time-of-flight information. Xenon 30-35 sarcoma antigen 1 Homo sapiens 82-86 19805177-7 2009 Coupled with targeted xenon biosensors, Hyper-SAGE offers another path to highly sensitive molecular imaging of specific cell markers by detection of exhaled xenon gas. Xenon 22-27 sarcoma antigen 1 Homo sapiens 46-50 19805177-7 2009 Coupled with targeted xenon biosensors, Hyper-SAGE offers another path to highly sensitive molecular imaging of specific cell markers by detection of exhaled xenon gas. Xenon 158-163 sarcoma antigen 1 Homo sapiens 46-50 19144758-2 2009 Here, we show that preconditioning with the anesthetic gas xenon activates hypoxia-inducible factor 1alpha (HIF-1alpha) and its downstream effectors erythropoietin and vascular endothelial growth factor in a time-dependent manner in the kidneys of adult mice. Xenon 59-64 hypoxia inducible factor 1, alpha subunit Mus musculus 108-118 19144758-2 2009 Here, we show that preconditioning with the anesthetic gas xenon activates hypoxia-inducible factor 1alpha (HIF-1alpha) and its downstream effectors erythropoietin and vascular endothelial growth factor in a time-dependent manner in the kidneys of adult mice. Xenon 59-64 erythropoietin Mus musculus 149-163 19144758-3 2009 Xenon increased the efficiency of HIF-1alpha translation via modulation of the mammalian target of rapamycin pathway. Xenon 0-5 hypoxia inducible factor 1 subunit alpha Homo sapiens 34-44 19144758-4 2009 In a model of renal ischemia-reperfusion injury, xenon provided morphologic and functional renoprotection; hydrodynamic injection of HIF-1alpha small interfering RNA demonstrated that this protection is HIF-1alpha dependent. Xenon 49-54 hypoxia inducible factor 1 subunit alpha Homo sapiens 203-213 19144758-5 2009 These results suggest that xenon preconditioning is a natural inducer of HIF-1alpha and that administration of xenon before renal ischemia can prevent acute renal failure. Xenon 27-32 hypoxia inducible factor 1 subunit alpha Homo sapiens 73-83 19224794-8 2009 RESULTS: Xenon significantly (P < 0.05) reduced myocardial infarct size compared with control (32 +/- 4 and 59% +/- 4% of the left ventricular area at risk; mean +/- sd) and enhanced phosphorylation of Akt and GSK-3beta. Xenon 9-14 AKT serine/threonine kinase 1 Rattus norvegicus 205-208 19224794-8 2009 RESULTS: Xenon significantly (P < 0.05) reduced myocardial infarct size compared with control (32 +/- 4 and 59% +/- 4% of the left ventricular area at risk; mean +/- sd) and enhanced phosphorylation of Akt and GSK-3beta. Xenon 9-14 glycogen synthase kinase 3 beta Rattus norvegicus 213-222 19224794-12 2009 CONCLUSIONS: These results indicate that xenon preconditioning reduces myocardial infarct size, phosphorylates Akt, and GSK-3beta, preserves mitochondrial function, and inhibits Ca(2+)-induced mitochondrial permeability transition pore opening. Xenon 41-46 AKT serine/threonine kinase 1 Rattus norvegicus 111-114 19224794-12 2009 CONCLUSIONS: These results indicate that xenon preconditioning reduces myocardial infarct size, phosphorylates Akt, and GSK-3beta, preserves mitochondrial function, and inhibits Ca(2+)-induced mitochondrial permeability transition pore opening. Xenon 41-46 glycogen synthase kinase 3 beta Rattus norvegicus 120-129 19244689-4 2009 It was shown that pharmacological activation of the hypoxia-inducible factor 1alpha pathway is organ protective, and recent studies demonstrated that isoflurane and xenon lead to hypoxia-inducible factor 1alpha upregulation, which is related to the preconditioning effect of the inhalational anaesthetics. Xenon 165-170 hypoxia inducible factor 1 subunit alpha Homo sapiens 52-83 19244689-4 2009 It was shown that pharmacological activation of the hypoxia-inducible factor 1alpha pathway is organ protective, and recent studies demonstrated that isoflurane and xenon lead to hypoxia-inducible factor 1alpha upregulation, which is related to the preconditioning effect of the inhalational anaesthetics. Xenon 165-170 hypoxia inducible factor 1 subunit alpha Homo sapiens 179-210 18571851-0 2008 Xenon induces transcription of ADNP in neonatal rat brain. Xenon 0-5 activity-dependent neuroprotector homeobox Rattus norvegicus 31-35 19020121-0 2008 Xenon induces late cardiac preconditioning in vivo: a role for cyclooxygenase 2? Xenon 0-5 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 63-79 19020121-17 2008 CONCLUSION: Xenon induces late myocardial preconditioning that is abolished by functional blockade of COX-2 activity. Xenon 12-17 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 102-107 18571851-3 2008 In this study we explored the gene transcription of activity-dependent neuroprotective protein (ADNP) in neonatal rat brain as consequence to xenon exposure, comparing the noble gas to nitrogen. Xenon 142-147 activity-dependent neuroprotector homeobox Rattus norvegicus 52-94 18571851-3 2008 In this study we explored the gene transcription of activity-dependent neuroprotective protein (ADNP) in neonatal rat brain as consequence to xenon exposure, comparing the noble gas to nitrogen. Xenon 142-147 activity-dependent neuroprotector homeobox Rattus norvegicus 96-100 18571851-6 2008 The differential expression of ADNP in the rat neonatal brain may account for the preconditioning and neuroprotective effects exerted by gas xenon. Xenon 141-146 activity-dependent neuroprotector homeobox Rattus norvegicus 31-35 17525587-8 2007 Xenon anesthesia decreased absolute rCBF by 34.7+/-9.8% in the cerebellum (P<0.001), by 22.8+/-10.4% in the thalamus (P=0.001), and by 16.2+/-6.2% in the parietal cortex (P<0.001). Xenon 0-5 CCAAT/enhancer binding protein zeta Rattus norvegicus 36-40 18344553-1 2008 BACKGROUND: The effects of xenon on regional cerebral blood flow (rCBF) are controversial. Xenon 27-32 CCAAT/enhancer binding protein zeta Rattus norvegicus 66-70 18344553-4 2008 rCBF was determined at baseline and during general anaesthesia induced with propofol and maintained with one minimum alveolar concentration xenon. Xenon 140-145 CCAAT/enhancer binding protein zeta Rattus norvegicus 0-4 18344553-10 2008 Voxel-based analysis showed an increase of rCBF in white matter and a relative decrease of rCBF during xenon anaesthesia in distinct grey matter regions, particularly the orbito- and mesiofrontal cortex, cingulate gyrus, thalamus, hippocampus and bilateral cerebellum (P<0.05 corrected). Xenon 103-108 CCAAT/enhancer binding protein zeta Rattus norvegicus 91-95 18344553-12 2008 CONCLUSIONS: Xenon exerted distinct regional effects on CBF: relative decreases in several cortical, subcortical, and cerebellar areas were accompanied by an increase in white matter. Xenon 13-18 CCAAT/enhancer binding protein zeta Rattus norvegicus 56-59 18199914-5 2008 A linear fit showed that in the lung parenchyma rho(TSI) = (0.97 +/- 0.03)rho(KES) + (0.00 +/- 0.05) for xenon and rho(TSI) = (1.21 +/- 0.15)rho(KES) + (0.0 +/- 0.1) for iodine. Xenon 105-110 rhodopsin Oryctolagus cuniculus 48-56 17959960-4 2007 METHODS: Xenon was selectively frozen to -139.2 degrees C from test gas mixtures at ambient pressure (STP). Xenon 9-14 thyroid hormone receptor interactor 10 Homo sapiens 102-105 18073551-3 2007 The authors show that xenon and isoflurane compete for the binding of the coagonist glycine on the NMDA receptor NR1 subunit. Xenon 22-27 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 113-116 18073551-9 2007 The loss of inhibitory effect of xenon and isoflurane in mutant NR1(F639A)/NR2A receptors is explained by increased glycine affinity of the mutant receptors, and inhibition is restored at low glycine concentrations. Xenon 33-38 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 64-67 18073551-9 2007 The loss of inhibitory effect of xenon and isoflurane in mutant NR1(F639A)/NR2A receptors is explained by increased glycine affinity of the mutant receptors, and inhibition is restored at low glycine concentrations. Xenon 33-38 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 75-79 17627347-0 2007 H(3) (+) as a trap for noble gases--2: structure and energetics of XH(3) (+) complexes from X=neon to xenon. Xenon 102-107 H3 clustered histone 14 Homo sapiens 0-4 17627347-1 2007 The affinity of H(3) (+) to combine with noble gases X has been investigated from neon to xenon using ab initio coupled cluster [CCSD and CCSD(T)] and density functional BH&HLYP levels of theory. Xenon 90-95 H3 clustered histone 14 Homo sapiens 16-20 18461940-2 2008 The 1.70 A resolution crystal structure of a cryptophane-derivatized benezenesulfonamide complexed with human carbonic anhydrase II shows how an encapsulated xenon atom can be directed to a specific biological target. Xenon 158-163 carbonic anhydrase 2 Homo sapiens 110-131 18516101-0 2008 ETA-receptor blockade impairs vasoconstriction after hemorrhage in xenon-anesthetized dogs treated with an AT1-receptor antagonist. Xenon 67-72 endothelin receptor type A Canis lupus familiaris 0-3 18516101-0 2008 ETA-receptor blockade impairs vasoconstriction after hemorrhage in xenon-anesthetized dogs treated with an AT1-receptor antagonist. Xenon 67-72 angiotensin II receptor type 1 Canis lupus familiaris 107-110 18516101-12 2008 Combined AT1+ETA-receptor blockade impaired vasoconstriction more than did AT1-receptor blockade alone, both during baseline xenon anesthesia and after hemorrhage. Xenon 125-130 angiotensin II receptor type 1 Canis lupus familiaris 9-12 18218690-9 2008 In voltage clamp, the selective M-channel blocker, XE-991, inhibited a K(+) current in GnRH neurons. Xenon 51-53 gonadotropin releasing hormone 1 Homo sapiens 87-91 18212564-0 2008 Intermitted pharmacologic pretreatment by xenon, isoflurane, nitrous oxide, and the opioid morphine prevents tumor necrosis factor alpha-induced adhesion molecule expression in human umbilical vein endothelial cells. Xenon 42-47 tumor necrosis factor Homo sapiens 109-136 18040673-8 2008 CONCLUSION: PCT confirmed the results of xenon-CT studies and was shown to allow better evaluation of tissue viability than noncontrast CT. Xenon 41-46 calcitonin related polypeptide alpha Homo sapiens 12-15 17620835-4 2007 In contrast, nitrous oxide, xenon, and ketamine produce analgesia, but weak hypnosis and amnesia, by inhibiting glutamate and nicotinic receptors and activating potassium "leak" channels such as TREK-1. Xenon 28-33 potassium two pore domain channel subfamily K member 2 Homo sapiens 195-201 17659475-3 2007 There are six main families of K2P channels and among these certain members of the TREK family (ie, TREK-1 and TREK-2) are activated by general anesthetic agents such as halothane, xenon and nitrous oxide. Xenon 181-186 keratin 76 Homo sapiens 31-34 17659475-3 2007 There are six main families of K2P channels and among these certain members of the TREK family (ie, TREK-1 and TREK-2) are activated by general anesthetic agents such as halothane, xenon and nitrous oxide. Xenon 181-186 potassium two pore domain channel subfamily K member 2 Homo sapiens 83-87 17659475-3 2007 There are six main families of K2P channels and among these certain members of the TREK family (ie, TREK-1 and TREK-2) are activated by general anesthetic agents such as halothane, xenon and nitrous oxide. Xenon 181-186 potassium two pore domain channel subfamily K member 2 Homo sapiens 100-106 17659475-3 2007 There are six main families of K2P channels and among these certain members of the TREK family (ie, TREK-1 and TREK-2) are activated by general anesthetic agents such as halothane, xenon and nitrous oxide. Xenon 181-186 potassium two pore domain channel subfamily K member 10 Homo sapiens 111-117 17525587-9 2007 On average, xenon anesthesia decreased absolute rCBF by 11.2+/-8.6% in the gray matter (P=0.008). Xenon 12-17 CCAAT/enhancer binding protein zeta Rattus norvegicus 48-52 17525587-12 2007 CONCLUSIONS: One MAC of xenon decreased rCBF in several areas studied. Xenon 24-29 CCAAT/enhancer binding protein zeta Rattus norvegicus 40-44 17442416-6 2007 Electrophysiological experiments confirmed the presence of an XE-991 sensitive current and Western blotting analysis revealed that KCNQ1 channel protein was present in the neonatal rat cardiomyocytes. Xenon 62-64 potassium voltage-gated channel subfamily Q member 1 Rattus norvegicus 131-136